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Touted among the major achievements in the diagnosis and management of 
Prostate cancer (PCa) in the past few decades has been, the dramatic decline of men with 
advanced/metastatic  PCa at diagnosis coupled with a significant improvement ( >90%) 
in the five and ten year survival rates of the disease.   Non-palpable PCa (potentially 
clinically treatable disease) now accounts for 70-80% of all newly diagnosed cases of 
PCa.  Preceding these changes by about a decade was the introduction of Prostatic 
Specific Antigen (PSA) into clinical practice; first as biomarker for monitoring response 
to therapy and subsequently as a complementary screening tool.  It is not surprising then 
that a cause-effect relationship has been suggested.  Like a double-edged sword, the use 
of PSA as a screening tool has also been blamed for the rise of unnecessary prostate 
related invasive procedures including biopsies and surgeries.  Some of the documented 
criticisms of PSA include its lack of specificity (elevated in inflammation) for PCa and 
the difficulty of establishing a cut-off value that is highly sensitive and specific for the 
disease.  It is estimated that perhaps up to half of the PCa diagnosis are patients whose 
tumors would have been clinically undetectable had PSA not been included in the 
screening process.  The dissatisfaction with PSA has created opportunities to search for 
novel biomarkers for screening and monitoring of treatment in PCa.  Some of the more 
xv 
novel biomarkers that have been examined as potential replacements for PSA are the 
RNA product prostate cancer antigen-3 (PCA 3), the enzyme alpha methylacyl-CoA, and 
the gene fusion product TMPRSS2-ERG.   More recently Zhang, Casiano and colleagues 
described an increased predominance of autoantibodies to Cyclin-B1 in the sera of PCa 
patients compared to controls with Benign Prostatic Hyperplasia (BPH).  All these efforts 
are in different stages of maturity but yet to have ground breaking clinical impact. 
We hereby examined the role of exosomes in PCa and a qualitative profile of its 
proteomic composition.  The higher levels of circulating exosomes in sera of PCa patients 
is directly prostate-derived and could be stress-induced as the non-cancer prostate stroma 
and the immune system interact with neoplastic cells. This could be reflected in some of 
the similarities in the proteomic profile of serum-derived exosomes and exosomes 
derived from direct PCa in vitro cell line cultures. Moreover, PCa has a higher incidence 
and a greater disease severity in non-Hispanic African Americans and this difference in 
disease biology can be reflected in the difference in the proteomic profile of exosomes 
across ethnicities/races.  Serum exosomes originate from a diverse population of normal, 
neoplastic or inflammatory cells.  Tumors do shed membrane vesicles directly into serum 
or extracellular space.  These vesicles are referred to as tumor derived exosomes (TEX).  
Our overall objective was to use a seroproteomics approach focused on profiling serum 
exosomes in PCa patients.  This profile would then be compared with that of non-cancer 
patients in an effort to identify proteins unique to cancer patients.  A comparative study 
across racial groups will help us begin to identify possible protein markers/players 
involved in determining disease aggressiveness. The project hopes to one day fill the gap 
of the lack of biomarker identification in PCa patients and perhaps give us potential 
xvi 
therapeutic targets to help lower morbidity in the black and indeed all cohorts of patients.  
It builds on preliminary data indicating that PCa patient sera have exosomes containing 
stress survival and cancer related proteins. 
 
1 
CHAPTER 1 
LOCALIZATION AND UP-REGULATION OF SURVIVIN IN CANCER 
HEALTH DISPARITIES: A CLINICAL PERSPECTIVE. 
 
 
 
 
 
 
 
 
 
 
 
 
Published: 
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RB, Esebanmen GE, Ashok A, Wall NR.  Localization and up regulation of Survivin in 
cancer health disparities: a clinical perspective. Biologics: Targets and Therapy, 9: 57-67, 
2015. 
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Abstract 
Survivin is one of the most important members of the inhibitors of apoptosis 
(IAP) protein family as it is expressed in most human cancers but is absent in normal, 
differentiated tissues.  Lending to its importance, Survivin has proven associations with 
apoptosis and cell cycle control and has more recently been shown to modulate the tumor 
microenvironment and immune evasion as a result of its extracellular localization.  Up 
regulation of Survivin has been found in many cancers including breast, prostate, 
pancreatic, and hematological malignancies and may prove to be associated with the 
advanced presentation, poorer prognosis and lower survival rates observed in ethnically 
diverse populations. 
 
Key Words: Survivin, cancer, exosomes, health disparity 
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Introduction 
 Cancer is a major public health problem in the United States and the world.  
Recent epidemiological statistics indicate that cancer will develop in one in three women 
and one in two men in the US over their lifetime.(Siegel et al., 2013)  The three most 
common cancers among males are prostate, colorectal and melanoma of the skin, and 
among females, breast, uterine corpus and colorectal.(Sharp et al., 2014)  Although 
deaths attributed to cancer have declined among both Caucasians and African Americans, 
African Americans continue to suffer a greater burden for each of the most common 
types of cancer.(Siegel et al., 2013)  This discrepancy recorded among cancer patients 
from different ethnicities is termed cancer health disparity.  The National Cancer Institute 
(NCI) defines cancer health disparity as an adverse difference in cancer incidence (new 
cases), cancer prevalence (all existing cases), cancer death (mortality), cancer 
survivorship, and burden of cancer or related health conditions that exist among specific 
population groups.(Siegel et al., 2013)  When investigating the factors that contribute to 
cancer health disparities, the most obvious are access to health care and socioeconomic 
status.(Beydoun & Beydoun, 2008, Guessous et al., 2010, Jadav et al., 2015)  However, 
evidence exists that dietary fat can influence carcinogenesis.(Tsai & Giovannucci, 2012)  
In 1982, the US National Academy of Sciences committee on Diet, Nutrition and Cancer, 
using both epidemiological and experimental data, concluded that a causal relationship 
between fat intake and the occurrence of cancer exists.(Council, 1982)  However, the 
strongest evidence that environmental factors give rise to an etiology of cancer comes 
from the studies of cancer incidence in different ethnic populations and their migrations 
and lifestyle habits.  Specifically, the adoption of a Westernized diet appears causal in the 
4 
significant increase in annual deaths, in native Japanese, from colon,(Takachi et al., 
2011) breast(Kono, 2010) and pancreatic cancers(Kasuga et al., 2013) upon their moving 
from Japan to the United States.  In addition, experimental animal studies agree that both 
specific and non-specific evidence exists for the occurrence of cancer being strongly 
associated with consumption of a diet high in fat.(Guthrie & Carroll, 1999)  
Contradictory studies also exist in which lifestyle factors in cancer incidence have been 
described.  Whereas years smoking and number of cigarettes smoked had a correlation 
with increased incidence of pancreatic cancer, there was no correlation with pancreatic 
cancer and body mass index, physical activity, alcohol, coffee and green tea 
consumption.(Nakamura et al., 2011) 
 Early detection is important in cancer discovery, treatment and survival.  In order 
to better understand cancer incidence and mortality in diverse populations it has become 
imperative that we identify and then characterize markers of cancer development and 
progression to include both pathways and molecular mechanisms associated with these 
disparities.  Given the strong link between cancer incidence, oxidative stress and diets 
high in fat,(De Pergola & Silvestris, 2013) we must map these associations and identify 
the survival entities and pathways as potential targets.  A long-term goal in health 
disparities research is to understand how an increase in oxidative stress will ultimately 
promote cancer cell resistance to therapy-induced death and how to overcome this 
resistance. 
 Survivin is an important member of the inhibitors of apoptosis (IAP) protein 
family because its tumor specific expression is unique out of all of the human gene 
products.(Reed, 2001)  Survivin expression is evident during embryonic and fetal 
5 
development but not in terminally differentiated tissue.(Li et al., 1998)  It is expressed in 
virtually all of the different types of human cancers (Table I), making Survivin an 
alluring protein in the study of carcinogenesis.(Andersen et al., 2007)  Survivin is 
referred to as a bifunctional protein, having essential roles in inhibiting apoptosis and 
controlling proper cell division.(Altieri, 2003)  In our most recent work we have begun to 
refer to Survivin as a multifunctional protein as it does much more, to include controlling 
diverse cellular functions, including surveillance checkpoints, suppression of cell death, 
the regulation of mitosis, and adaptation to unfavorable environments.(Altieri, 2003, 
2006) 
 
Localization of Survivin 
 The multifaceted functionality of Survivin is still being intensely scrutinized, and 
it appears that protein compartmentalization may be important.  Survivin has been shown 
to localize in mitochondria, where it modulates tumor cell apoptosis similar to the Bcl-2 
family.(Dohi, Beltrami, et al., 2004b)  Its localization to nucleus and cytosol confers its 
role in mitosis regulation and apoptosis inhibition, respectively.(Fortugno et al., 2002)  
Furthermore, we have identified the existence of Survivin extracellularly, contained in 
small membrane bound vesicles known as exosomes (Figure 1), and have shown that 
exosome-bound Survivin protein can be secreted by cancer cells to be taken up by 
surrounding cells, producing a field effect that confers a general stress-survival 
phenotype.(Khan et al., 2009, Khan S et al., 2011, Webber et al., 2015). 
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Table: Influence of Survivin on Clinical Prognosis. 
Cancer type On 
prognosis/staging 
of the disease 
Survivin 
expression 
Reference 
1. Breast cancer Good to poor Moderate 
to high  
Kalla Singh 2010, Adamkov 
2012, Rexhepaj 2010, Xu 
2012, Dedić Plavetić 2013, 
Span 2006, Li 2004, Boidot 
2009, Khan 2014 
2. Prostate cancer Fair to poor Moderate 
to high 
Zaffaroni 2005, Shariat 2004, 
Koike 2008, Zhang 2009 
3. Pancreatic 
cancer  
Poor High Xie 2013 
4. Leukemia Good to poor Low to 
high 
Fulda 2009, Kamihira 2001, 
Park 2011 , Kelly 2011, 
Troeger 2007, Esh 2011, Tyner 
2012, Ahmed 2012, Morrison 
2012, Grzybowska-Izydorczyk 
2010, Carter 2012, Small 2010 
5. Other cancers Good to poor Moderate 
to high 
Waligorska-Stachura 2009 
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Figure 1.  Exosomes play important roles in intercellular communication.  A tumor 
cell communicates with the tumor microenvironment and may be able to affect cancer cell 
aggressiveness as a result of the protein, RNA and/or miRNA payload found within.  One 
potentially important protein to the proliferative, invasive or therapy resistance nature of 
the tumor is Survivin which has been found released from cancer cells in exosomes. 
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Consistent with Survivin’s association with unfavorable clinicopathological parameters, 
extracellular trafficking of Survivin throughout the tumor microenvironment could be 
responsible for augmenting the aggressive status of a tumor while prohibiting or 
minimizing therapeutic results.(Li F et al., 1999, Li & Ling, 2006, Khan et al., 2009) 
This review focuses on the multifaceted roles of Survivin in cancer biology, its cellular 
localization and its cancer health disparity-specific up regulation, specifically in breast, 
prostate, pancreas and hematological cancers. 
 
Nuclear Survivin as a Cell Cycle Regulator 
 Nuclear Survivin is known to be a cell cycle associated protein.  Investigations of 
cell division regulation during the depletion of Survivin by siRNA demonstrated an 
increase in mitotic arrest and chromosomal misalignment.  Furthermore, this study 
confirmed that Survivin is involved in microtubule assembly and centromere stabilization 
during mitosis.(Yang et al., 2004)  Survivin’s role in mitosis regulation is associated with 
its involvement in the chromosomal packaging complex and its contribution to the 
formation of the mitotic spindle.(Altieri, 2008, Church & Talbot, 2012) IAP family 
proteins cIAP2 and Survivin have been shown to dramatically increase upon exposure to 
hypoxia.(Dong et al., 2001, Dohi, Okada, et al., 2004)  Furthermore, survivin’s promoter 
has been shown to contain 3 putative HIF-1 binding or response elements.(Zagorska & 
Dulak, 2004)  Nuclear Survivin was found to be distinctly involved in the prognosis of 
different cancers as will be discussed in our specific cancers section. 
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Cytoplasmic/Mitochondrial Survivin as an Apoptosis Inhibitor 
 Survivin’s ability to interfere with cellular death pathways appears to reside in the 
cell’s cytoplasm.  Survivin localizes to the mitochondria(Dohi, Beltrami, et al., 2004a) 
and therefore may provide, like Bcl-2, a role in mitochondrial stability.  Cellular stress 
was shown to modulate the expression and localization of Survivin with hypoxia-induced 
Survivin found exclusively in the mitochondria.  Furthermore, upon apoptotic 
stimulation, mitochondrial Survivin is rapidly released to the cytosol where its 
cytoprotective effects prevent the activation of the initiator caspase 9.(Dohi, Beltrami, et 
al., 2004a) 
 Early studies showed that Survivin and XIAP protected cells from undergoing 
caspase-dependent apoptosis. Subsequently, in vitro binding experiments showed that 
Survivin, like XIAP and other IAPs, bound to the terminal effector cell death proteases, 
caspase 3 and 7, but not to initiator caspase 8.(Tamm et al., 1998)  Controversy in the 
field arose when a study by the Altieri group showed that Survivin did not inhibit caspase 
3 activity and where recombinant Survivin failed to decrease recombinant caspase 3 
activity in vitro.(Banks et al., 2000)  Current evidence suggests that Survivin acts on 
caspases in an indirect manner by binding to the hepatitis B X interacting protein 
(HBXIP) and forming a complex with pro-caspase 9, inhibiting the apoptosome 
formation.(Marusawa et al., 2003) This Survivin-HBXIP complex, not individual 
Survivin or HBXIP proteins, binds to pro-caspase 9 and works to prevent recruitment of 
apoptosis activating factor 1 (Apaf1) thus suppressing intrinsic apoptosis.  In addition, 
Survivin binds to and regulates the stability of XIAP, which is a direct caspase 3 and 9 
inhibitor.(Church & Talbot, 2012)  More specifically, the formation of a Survivin-XIAP 
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complex promotes increased XIAP stability, protecting XIAP from proteasomal 
degradation, resulting in a facilitated inhibition of caspase-dependent cell death.(Dohi, 
Okada, et al., 2004) 
 
Extracellular Survivin as a Modulator of Tumor Microenvironment 
 Survivin has recently been shown to exist in the extracellular space,(Khan et al., 
2009) via 40-100 nm membrane vesicles called exosomes.(Khan S et al., 2011)  Various 
cell types, such as B- and T- lymphocytes, dendritic cells, neurons, intestinal epithelial 
cells, as well as tumor cells release exosomes.(Denzer K et al., 2000, Keller S et al., 
2006, Simpson RJ et al., 2009, Greening et al., 2015)  In particular, it has been shown 
that both human and mouse tumor cells release tumor cell-derived exosomes (TEX) 
constitutively.(Wolfers J et al., 2001)  Additionally, specific protein content found both 
on and within TEX give an indication of their functional and biological roles, and their 
cell of origin, making TEX excellent biomarkers.(Zitvogel L et al., 1998, Andre et al., 
2002, Wieckowski E & TL, 2006, Aleckovic & Kang, 2015)  Early detection, aggressive 
determination, and therapeutic efficacy may one day be possible through the use of these 
exosomes and their contents. 
 Our lab has shown that the extracellular pool of Survivin has the ability to cause 
neighboring cancer cells to increase resistance to therapy, rapidly proliferate and acquire 
an increased potential to become invasive in vitro,(Khan et al., 2009) providing a 
protective role to the neighboring tumor cells.(Khan S et al., 2011)  The ability of 
extracellular Survivin to cause these effects in the surrounding cancer cells correlates 
with the fact that Survivin overexpression is observed in virtually every human cancer 
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type.(Altieri DC, 2003a)  TEX may also be used as a tool to detect malignant 
conditions.(Aleckovic & Kang, 2015)  Serum taken from cancer patients has an increased 
level of TEX,(Ginestra A et al., 1998, Ginestra A et al., 1999) which has a positive 
correlation with the progression of the tumor.(Khan S et al., 2011)  In addition to serum, 
TEX were shown to be isolated from malignant tumor fluids, urine,(Nilsson et al., 2009, 
Rolfo et al., 2014) ascites fluids(Adams et al., 2005, Shender et al., 2014) and pleural 
effusions.(Andre et al., 2002, Park et al., 2013)  We have recently shown that exosomal 
Survivin may be a useful tool for early detection, diagnosis, and even monitoring prostate 
cancer progression.(Khan et al., 2012)  Newly diagnosed and advanced prostate cancer 
patients with high or low-grade cancer had significantly higher levels of exosomal 
Survivin compared to control subjects or patients with pre-inflammatory benign prostatic 
hyperplasia (BPH).(Khan et al., 2012) 
 
Survivin in Cancer Immunity Evasion 
 Survivin has been ascribed multiple roles not only in malignancy, but also in 
immunity and differentiation.(Zangemeister-Wittke & Simon, 2004)  Survivin has been 
shown to be essential for T-cell maturation, homeostasis and proliferation at various 
stages of development.(Xing et al., 2004)  It has also been shown to modulate peripheral 
blood leukocytes (PBL) when in the extracellular space by binding to leukocytes, thereby 
inducing molecular processes implicated in the pathogenesis of inflammation.(Mera et 
al., 2008)  On the basis of the literature and our data, Survivin may be said to exhibit 
duplicity in cancer immunity as it can act as a tumor associated antigen, or modulate 
immune environment to permit tumor growth. 
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 Recently, an artificial antigen-presenting cell, developed to study anti-Survivin 
CD4+ T-cell responses in cancer patients, was shown to elicit both Th1 and Th2 
responses against Survivin.  The level of avidity was appropriate to recognize tumor 
cells.(Tanaka et al., 2011)  Previously, constructed DNA-peptide complexes (mimovirus) 
of Survivin epitopes, have been shown to stimulate strong cytotoxic T lymphocyte 
(CTL)-mediated long-term memory of murine immune response and exact a high anti-
tumor effect in BALB/c mice.(Yang et al., 2008)  Furthermore, a DNA construct 
encoding a secreted version of Survivin, along with a plasmid coding for murine 
granulocyte-macrophage colony-stimulating factor (GM-CSF) as a molecular adjuvant, 
were observed to elicit humoral responses against Survivin in sera collected from mice.  
IgG2a antibody was the prevalent antibody sub-class, thereby implicating the induction 
of a Th1-CD4+ cellular response.(Lladser et al., 2006) 
 We have recently shown that when T-cell cultures were incubated with Survivin, 
surface binding and intracellular uptake of Survivin by these T-cells occurred.  Upon 
further investigation, a Survivin-associated decreased proliferation was observed in these 
T-cells.  In addition, analysis of CTLs revealed a reduction in their functional 
cytotoxicity.  However, Treg (T-regulatory cell) function remained unaltered. 
Importantly, the numbers of Th1 and Tc1 cells were significantly reduced, together with 
the cytokines associated with them (IFN-γ and IL-2), while an increase in IL-4+, IL-5+ 
and IL-13+ T-cells was observed. These results suggest a skewing from a type 1 response, 
which mediates immunity with cytokines that enhance cellular cytolytic activity and can 
elicit an effective anti-tumor response to a type 2 T-cell response which does not lead to 
tumor rejection and is frequently observed in cancer patients.(Wan, 2010, Amarnath et 
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al., 2011, Pietra et al., 2012, Jutzy et al., 2013)  The verification and molecular 
mechanism underlying this Th cell plasticity is yet to be fully elucidated. 
 
Cancer Specific Up Regulation of Survivin: Breast Cancer 
 Breast cancer is the second most common cancer type (following lung cancer) and 
the most common cancer among women worldwide.  It is estimated that in the United 
States alone there are nearly 3 million women with diagnosed breast cancer and 
approximately 227,000 more will be added to that number this year.(Siegel et al., 2013)  
African American women are more likely than all other women to die from breast cancer 
as their tumors often are discovered at a later, more advanced stage, leaving them fewer 
treatment options.(Dehal et al., 2013, Johnson et al., 2013) There are several pathways 
involved in breast cancer pathogenesis with pathways of tumor cell death playing an 
important role in its development and maintenance.  Among the proteins involved in cell 
death/survival pathways, Survivin is one of the most studied.  Using serial analysis of 
gene expression (SAGE), Survivin was found to be the fourth highest expressed 
transcript in a number of common cancers including breast cancers.(Velculescu et al., 
1999)  In a study examining the interaction of the insulin-like growth factor II and 
Survivin, Kalla Singh S et al, found that high IGF-II expression-regulation of Survivin 
correlated and was significantly higher in African Americans than in Caucasians.(Kalla 
Singh et al., 2010)  In this study it was shown that IFG-II regulates Survivin, leading to 
inhibition of mitochondrial membrane depolarization, cell survival and chemoresistance.  
Furthermore, the effect of IGF-II and IGF-II siRNA on the expression of Bcl-2, Bcl-XL 
and Survivin in African American and Caucasian breast cancer cells was measured.  IGF-
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II expression was shown to be causative in the upregulation of these antiapoptotic 
proteins, while IGF-II siRNA was prohibitive.(Kalla Singh et al., 2010) This intriguing 
observation will require further investigation. 
 The different sub-cellular pools of Survivin in breast cancer appear to have 
distinct functions.  Adamkov et al, suggested that nuclear staining of Survivin antigen 
could be used as a marker of the degree of neoplasia,(Adamkov et al., 2012) while 
Rexhepaj et al, suggested that increased levels of nuclear Survivin are associated with a 
proliferative phenotype.(Rexhepaj et al., 2010)  One thing that is clear is that Survivin 
plays a key role in the initiation and progression of breast cancer.  High mRNA 
expression was found to be an independent prognostic marker in breast cancer 
patients(Xu et al., 2012) and Survivin up regulation significantly correlated to lymph 
node involvement, tumor stage and histological type.(Dedić Plavetić et al., 2013)  By 
contrast, others have shown that high levels of its expression are associated with a 
beneficial response to chemotherapy.(Span et al., 2006)  This could be due to alternative 
splicing of Survivin.  Multiple studies demonstrate that alternative splicing patterns are 
altered during cancer progression.(Li, 2004)  Several different mechanisms contribute to 
changes in the regulation of alternative splicing including stress, stimulation of receptors 
by growth factors, cytokines, or hormones, etc.  Survivin, to date, has six different 
described variants with different apoptotic properties and intracellular localization 
(Figure 2).(Necochea-Campion et al., 2013)  Protein and mRNA levels of the pro- and 
anti-apoptotic isoforms of Survivin correlate with cancer prognosis.(Boidot et al., 2009) 
 Early diagnosis of breast cancer is challenging due to a lack of serum biomarkers 
and inadequate as it is performed through invasive means such as needle biopsy, scanning  
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Figure 2.  Splicing of the human survivin pre-mRNA produces six different splice 
variants.  With the exception of survivin- and survivin-2B, survivin-WT, survivin-
ΔEx3, survivin-3B, and survivin-
phenotypes.  The survivin-2B has been shown to have either a favorable or unfavorable 
association depending upon the cancer type it is expressed in, and survivin-
be determined. 
 
 
 
 
 
 
 
16 
and invasive pathological examination.  Despite the availability of numerous diagnostic 
and prognostic methods, there remains a need for an easy, sensitive and non-invasive way 
to track tumor activity.  We propose that through analysis of tumor exosomes and by 
specifically assaying these exosomes for tumor-specific antigens such as Survivin, XIAP, 
cIAP1/2, chaperone proteins such as HSP70 and 90, just such a biomarker discovery may 
one day be realized.  We have found an extracellular Survivin pool in serum exosomes in 
prostate(Khan et al., 2012) and breast cancers.(Khan et al., 2014)  In these breast cancer 
patients’ sera, we found Survivin levels and exosome numbers to be significantly 
increased over controls with a disparate expression of the Survivin splice variants similar 
to that observed in tissues. It is important though that we recognize the possible 
confounding factors such as co-morbidities, psychological complications, genetics, and 
environmental exposures that could affect these results. 
 
Cancer Specific Up Regulation of Survivin: Prostate Cancer 
 Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer in men 
and the second leading cause of male cancer deaths in the U.S., accounting for 238,590 
new cases and 29,720 deaths in 2013.(Brawley, 2012b, Siegel et al., 2013) These 
statistics have undergone minimal changes despite advances in screening and early 
diagnosis and therefore still require a significant investment if prostate cancer is to be 
defeated.  As has recently been described by our colleagues, African American men have 
a growing disparity in their prostate cancer incidence and mortality compared to other 
ethnic groups,(Basu et al., 2011) and they present with the disease at a much younger age 
than do Caucasian men which is a trait common in more aggressive cancers.(Hoffman et 
al., 2001, Karami et al., 2007) 
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 Survivin is expressed in prostate cancer and has been shown to be up regulated in 
order to protect the prostate cancer microenvironment against apoptosis and oxidative 
stress-induced damage.(Zaffaroni et al., 2005)  Survivin therefore directly and/or 
indirectly influences cell survival and death. Shariat et al., using immunohistochemistry, 
compared Survivin protein expression in normal and malignant prostate tissue and lymph 
node tissue from prostate cancer patients.  There appeared to be a gradual but consistent 
rise of Survivin expression from normal prostate specimens (36%), to prostate cancer 
(71%), with the highest expression found in metastatic lymph nodes (81%).(Shariat et al., 
2004)  Survivin expression therefore seemed to correlate with the degree of transition 
from normal prostate epithelia to a more aggressive form of prostate cancer (metastatic 
prostate cancer). 
 Our group recently looked at relative levels of Survivin in the sera of prostate 
cancer patients and compared it to that of patients with BPH and from subjects with no 
diagnosis of cancer or BPH.(Khan et al., 2012)  Survivin levels proved to exhibit a 
stronger correlation in our hands than prostate specific antigen (PSA) when it came to 
distinguishing the two clinical conditions.  We therefore propose that exosomal Survivin 
evaluation should be given serious consideration as a plausible biomarker for early 
detection of prostate cancer and perhaps could be used to monitor treatment efficacy and 
disease recurrence.  Higher levels of not only Survivin, but its splice variants 2B and 2α, 
both in vitro and in tissue, seem to correlate with prostate cancer cell proliferation and a 
more aggressive phenotype.(Koike et al., 2008)  The intracellular compartment 
localization of Survivin has been suggested to be of prognostic value.  When tissues of 
patients with locally advanced prostate cancer were stained and examined for Survivin, 
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patients with higher levels of intranuclear Survivin exhibited improved survival, whereas 
those with higher levels of cytoplasmic Survivin exhibited a poorer prognosis.(Zhang et 
al., 2009) 
 In summary, Survivin, in prostate cancer has a dual role as an inhibitor of 
apoptosis and cell cycle mediator.  Its level of expression appears to correlate with the 
progression from normal to indolent and to a more aggressive form of prostate cancer.  
Our demonstration of exosomal Survivin in the plasma of patients with newly diagnosed 
low-grade prostate cancer(Khan et al., 2012) provides a rationale for studies to 
investigate the utility of exosomal Survivin as an early, easily measured biomarker for 
prostate cancer diagnosis as well as a marker to monitor treatment efficacy and tumor 
recurrence. 
 
Cancer Specific Up Regulation of Survivin: Pancreatic Cancer 
 Cancer of the pancreas is the fourth most common cause of cancer death in men 
and women in the United States.  In 2013, an estimated 45,220 new cases and 38,460 
deaths from pancreatic cancer occurred.(Siegel et al., 2013)  It is a highly malignant 
disease and lacks clear early warning signs or symptoms thus remaining silent in its 
victims until it is well advanced.  The vast majority of patients are not diagnosed until 
stage III or IV and once diagnosed exhibit a median survival of 4-8 months with a 5-year 
survival rate being <5%.(Lowenfels & Maisonneuve, 2006)  Risk factors include gender, 
age, diabetes, chronic pancreatitis, family history, smoking, alcohol abuse and possibly 
diets high in fat.(Lowenfels & Maisonneuve, 2006)  Early diagnosis continues to be the 
greatest obstacle and there is an urgent need for screening biomarkers. 
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 Pancreatic cancer incidence in the United States is higher in African Americans 
and Hispanics than in Caucasians.(Gordis, 1993, Woutersen et al., 1999) In a number of 
recent studies, the risk factors in men (cigarette smoking and diabetes mellitus) and 
women (moderate/heavy alcohol consumption and an elevated body mass index 
(obesity)), explain almost the entire African American/non-Hispanic White disparity in 
incidence.  In the absence of these risk factors, pancreatic adenocarcinoma incidence 
rates among African Americans do not exceed those of Caucasians from either men or 
women.(Chang et al., 2005, Hayanga, 2005, Singal et al., 2012)  In 2003, a group at the 
Barbara Ann Karmanos Cancer Institute analyzed a group of pancreatic cancer patients 
(166 African American, 244 Caucasian) for clinicopathologic characteristics of the 
disease as well as immunohistochemical expression of commonly found pancreatic 
cancer biomarkers: Fas, FasL, p21/waf-1, p27, p53 and Her2.  They also investigated the 
presence and types of K-ras mutations at codon 12.(Pernick et al., 2003)  African 
Americans were found to have significantly higher rates of K-ras mutations than did 
Caucasians, and their treatment with chemotherapy or radiation therapy was also much 
less effective than that recorded in Caucasians.  African Americans more frequently than 
Caucasians were found with positive surgical margins and many clinicopathologic 
variables such as median survival, 5-year survival, and stage at presentation were 
different.  African Americans were less immunoreactive to Fas expression and had a 
much stronger Her2 expression than did Caucasians.(Pernick et al., 2003) 
 As in prostate and breast cancer as previously discussed, epidemiological 
evidence exists for a strong association between pancreatic cancer and a high 
consumption of dietary fat.  Dietary fat is made up of fatty acids and lipids that are 
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metabolized into arachidonic acid.  The key enzymes for arachidonic acid metabolism are 
lipoxygenases (LOXs) and cyclooxygenases (COXs) which outside of dietary fat research 
have been shown associated with the development and progression of pancreatic 
cancer.(Ding et al., 2001)  LOX and COX inhibitors prohibit the continued progression 
of pancreatic cancer and induce intrinsic mitochondria-associated apoptotic cell 
death.(Tong et al., 2002) 
 There have been numerous studies performed on the prognostic implications of 
Survivin in pancreatic cancer.  A high expression of Survivin was found to be related to 
shorter survival in patients with resected pancreatic adenocarcinoma.(Xie et al., 2013)  In 
contrast, high nuclear levels of Survivin predicted better prognosis than cytoplasmic 
Survivin.(Tonini et al., 2005)  Furthermore, Sagol et al and Sun et al showed no 
significant association between Survivin and long-term survival.(Sagol et al., 2005, Sun 
et al., 2007) Targeting Survivin early on in the process could play an invaluable role in 
preventing the progression to malignancy.  In addition, a screening biomarker that could 
potentially detect early stages of the disease is of utmost importance. 
 
Cancer Specific Up Regulation of Survivin: Hematological Malignancies 
 Hematological malignancies such as leukemia, lymphoma, myeloma and 
myelodysplastic syndromes affect the bone marrow, the blood cells, the lymph nodes and 
other parts of the lymphatic system.  These pathologies are interrelated, likely the result 
of acquired changes to the DNA of a single stem cell.  Approximately 140,000 people 
will be diagnosed with leukemia, lymphoma or myeloma, accounting for approximately 9 
% of all new cancers diagnosed each year in the United States.(Society, 2012)  Of 
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particular interest is multiple myeloma (MM), which accounts for approximately 10 % of 
all hematologic malignancies diagnosed in the United States annually.(Pulte et al., 2012)  
Among the hematological malignancies, MM is known to affect individuals from 
ethnically diverse populations in a disparate manner. 
 In accordance with reports for many types of solid tumors,(Church & Talbot, 
2012, Waligorska-Stachura et al., 2012) cancer specific up regulation of Survivin also 
occurs in hematological malignancies,(Fulda, 2009, 2012) though to date there have been 
no published reports taking ethnicity into account.  In hematological cancers, expression 
of Survivin is associated with poor clinical outcomes and resistance to 
chemotherapy.(Adida et al., 2000, Kamihira et al., 2001, Kelly, 2011, Park et al., 2011)  
Survivin expression levels are linked to risk of early relapse in pediatric B-cell acute 
lymphoblastic leukemia (ALL)(Troeger et al., 2007, A. Esh, 2011, Tyner et al., 2012) 
and to tumor aggressiveness(Ahmed et al., 2012) and chemoresistance in adult 
ALL.(Morrison et al., 2012) 
 High levels of Survivin expression have also been linked to cell proliferation and 
antiapoptotic characteristics in chronic myelogenous leukemia (CML),(Wang et al., 
2005) and chronic lymphocytic leukemia (CLL).(Grzybowska-Izydorczyk et al., 2010)  
In acute myeloid leukemia (AML), levels of Survivin expression were found to be 
significantly predictive of shorter overall and event-free survival.(Carter et al., 2012) In 
addition, the highest Survivin expression levels are detected in the CD34(+)CD38(-) 
AML stem/progenitor cell populations,(Carter et al., 2012) further validating Survivin’s 
potential as a prognostic biomarker and therapeutic target.  Overexpression of Survivin in 
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CD34+ hematopoietic cells has been found to induce hematological malignancies in vivo, 
suggesting that it has a role in the development of these diseases.(Small et al., 2010) 
 Localization of Survivin to the nucleus versus cytoplasm is very important 
because the functional dynamics of Survivin are dependent on the site of Survivin 
expression.(Kumar et al., 2012)  Using chemotherapeutic drugs in hematologic cancer, 
Bernardo et al., reported that cytoplasmic Survivin was more relevant to the apoptotic 
index than that associated with nuclear Survivin.(Bernardo et al., 2012) Investigating 
Survivin’s cellular locations, alternative splice variant profiles within the context of 
cancer health disparities and novel therapeutic modalities will continue to be important 
areas of study. 
 
Liquid Biopsy 
The tumor microenvironment is being increasingly recognized as providing many 
key factors necessary for many of the stages of disease progression including local 
resistance, immune escape, and distant metastasis.  Understanding this tumor 
microenvironment, including the cells involved and the communications ongoing 
between them will continue to prove instrumental in our understanding of cancer and 
eventually our ability to control it if not terminate it.  In order to fully “learn the 
language”, there is a need for new biomarker discovery.  Specifically, biomarkers that are 
easily isolated and identified from blood, urine, saliva, cerebral spinal fluid, ascites, etc., 
as well as from tissue biopsies, will need to be identified. The term “liquid biopsy” has 
been used recently to describe the source of these biomarkers and could be defined as 
broadly as circulating tumor cells, circulating tumor DNA, exosomes and 
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secretomes.(Rolfo et al., 2014)  Differential expression of exosomal Survivin may serve 
as a diagnostic and or prognostic marker, in early cancer patients and may soon lead to 
the development of potential therapeutics for the treatment of these diseases. 
 
Conclusions 
 Most efforts on the identification of candidate cancer biomarkers, and on 
analyzing differences in the cancer biology that exists between African Americans and 
Caucasian patients have focused on gene expression differentials in tumor tissues, 
epigenetic issues such as methylation patterns and on single nucleotide polymorphisms 
(SNPs).  While these efforts have been necessary in providing important clues for 
understanding biochemical mechanisms associated with cancer health disparities, it is 
also imperative to develop non-invasive approaches that analyze indirectly and early in 
the disease process, the molecular profiles of tumors.  One recent study has investigated 
the -31G>C promoter polymorphism across approximately 7,500 cancer cases and 9,000 
controls.(Qin et al., 2014) This polymorphism was significantly associated with an 
increased cancer risk in colorectal, gastric, and urothelial cancers.  In contrast, this SNP 
was remarkably decreased in patients with hepatocellular carcinoma.  With regard to 
ethnic diversity, this SNP was shown to increase cancer risk in Asian populations(Qin et 
al., 2014) as well as a higher Wilms’ tumor risk in Serbian children.(Radojevic-Skodric 
et al., 2012) Findings such as these encourage us to not only look at the overall 
abundance of gene or protein products in racial disparities and cancer but to look deeper 
into the minutia that may have been historically overlooked and may provide important 
insights not before recognized as factors in cancer development and resistance. 
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Recent studies have shown that small membrane-bound vesicles called exosomes 
constitute the latest mode of intercellular information transfer or communication.  This 
exchange of molecular information is facilitated by their unique composition, which is 
enriched with enzymes, structural proteins, adhesion molecules, lipid rafts, microRNA 
and RNA.  Importantly, cancer cells have been shown to secrete more exosomes than do 
their normal counterparts indicating that exosomes can be used as diagnostic markers and 
their active secretion has functional implications.  In addition, recent studies revealed that 
genes involved in inflammation and autoimmune responses are differentially up regulated 
in cancer patients compared to controls.  This could imply that differences in antitumor 
immune responses may exist between racial groups in tumors. 
 It is very important to specifically target Survivin in a defined location for 
therapeutic purposes.  Survivin is a unique inhibitor of apoptosis with triple functionality: 
in cell cycle regulation when it is present in the nucleus, inhibition of apoptosis when it is 
in the mitochondria, and resistance to chemotherapy when it exists in the tumor 
microenvironment packaged in exosomes.  Survivin’s up regulation in specific cancers, 
in addition to its presence in serum exosomes, make it an important molecule both as a 
diagnostic as well as prognostic marker.  Unfortunately, controversy exists as to whether 
Survivin expression is favorable or unfavorable in the outcome of cancer.  Survivin 
expression is an unfavorable prognostic indicator in esophageal, hepatocellular, and 
ovarian cancers, cholangiocarcinoma, and endometrial cancers but has associated 
favorable outcomes in gastric, bladder, breast, ependymoma osteosarcoma and pancreatic 
ductal adenocarcinomas.(Li et al., 2005, Carter et al., 2012) To validate its role, a large 
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number of case-control studies need to be adapted.  Subsequent studies exploiting the 
exosomal packaging of Survivin may also one day be used in cancer therapeutics. 
 In conclusion, this review addresses an urgent need in the fight against cancer 
health disparities: the need to identify and evaluate novel serum biomarkers such as 
Survivin and its alternative splice variants for non-invasive early detection of cancer in 
interventions that can be tailored to Americans of different ethnicities, ultimately, paving 
the way for future studies focused on analyzing these biomarkers in larger cohorts of 
ethnically diverse cancer patients. 
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Abstract 
Background: Survivin is expressed in prostate cancer (PCa), and its downregulation 
sensitizes PCa cells to chemotherapeutic agents in vitro and in vivo.  Small membrane-
bound vesicles called exosomes, secreted from the endosomal membrane compartment, 
contain RNA and protein that they readily transport via exosome internalization into 
recipient cells.  Recent progress has shown that tumor-derived exosomes play multiple 
roles in tumor growth and metastasis and may produce these functions via immune 
escape, tumor invasion and angiogenesis.  Furthermore, exosome analysis may provide 
novel biomarkers to diagnose or monitor PCa treatment. 
Methods:  Exosomes were purified from the plasma and serum from 39 PCa patients, 20 
BPH patients, 8 prostate cancer recurent and 16 healthy controls using ultracentrifugation 
and their quantities and qualities were quantified and visualized from both the plasma and 
the purified exosomes using ELISA and Western blotting, respectively. 
Results:  Survivin was significantly increased in the tumor-derived samples, compared to 
those from BPH and controls with virtually no difference in the quantity of Survivin 
detected in exosomes collected from newly diagnosed patients exhibiting low (six) or 
high (nine) Gleason scores.  Exosome Survivin levels were also higher in patients that 
had relapsed on chemotherapy compared to controls. 
Conclusions:  These studies demonstrate that Survivin exists in plasma exosomes from 
both normal, BPH and PCa subjects.  The relative amounts of exosomal Survivin in PCa 
plasma was significantly higher than in those with pre-inflammatory BPH and control 
plasma.  This differential expression of exosomal Survivin was seen with both newly 
diagnosed and advanced PCa subjects with high or low-grade cancers.  Analysis of 
39 
plasma exosomal Survivin levels may offer a convenient tool for diagnosing or 
monitoring PCa and may, as it is elevated in low as well as high Gleason scored samples, 
be used for early detection. 
 
Key Words: biomarker, resistance, early detection, prostate, Survivin 
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Introduction 
Worldwide, prostate cancer (PCa) is the second most frequently diagnosed cancer 
and the sixth leading cause of cancer death in males (Jemal et al., 2010, Jemal et al., 
2011).  Increasing age, ethnicity and family history are the only established risk factors 
and there are no known preventable risk factors established to date (Jemal et al., 2011).  
Prostate cancers (PCa) are generally slow-growing malignancies that are characterized by 
an imbalance in the rates of cell division and cell death (Lu S et al., 1999).  Surgery and 
radiation therapy are effective for localized disease but there is no effective treatment 
strategy for recurrent or metastatic PCa that has failed surgery, radiation or hormonal 
therapy (Klein EA & Kupelian PA, 2003).  An important challenge to develop treatments 
that are more effective depends upon our understanding of the molecular mechanism(s) 
of PCa progression, which will lead us to identify many potential therapeutic target genes 
and processes that are involved in apoptosis, cell proliferation, metastasis, and growth 
factor signaling.  Total prostate-specific antigen (PSA) has revolutionized PCa screening 
and has resulted in an overall decrease in PCa metastasis and death (Shariat et al., 2011).  
Unfortunately, the application of PSA screening has also led to over-detection and 
overtreatment as PSA is neither cancer specific nor a surrogate for the biologic behavior 
of PCa (Han et al., 2003, Shariat et al., 2011).  Elevations in PSA levels can reflect a 
cancer presence but can also be present as a result of infection, chronic inflammation or 
benign prostatic hyperplasia (BPH) (Freedland et al., 2005, Bjartell et al., 2011).  BPH 
has been shown to exist in greater than 70% of men over the age of 70 but is not 
considered to be a precursor of prostate cancer though they frequently coexist (Chang et 
al., 2012).  It is therefore necessary to continue to screen for biomarkers that are cancer-
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specific and that are detectable early in the course of the disease. 
The processes of both cell survival and cell death have involved highly regulated 
signaling pathways that are currently the subject of intense investigation.  It is known that 
regulation of apoptosis has a central role in the development of prostate cancer and its 
progression to an androgen-independent state, which is due, in part to up regulation of 
antiapoptotic genes after androgen deprivation (Li Y et al., 2004, Zhang M et al., 2005, 
Guo Z et al., 2006).  Several lines of evidence suggest that one of the main events 
associated with progression after therapeutic failure is increased resistance to apoptosis 
(Denmeade SR, 1996, Howell SB, 2000), mainly due to the up regulation of antiapoptotic 
genes, including Bcl-2, Bcl-XL, Mcl-1 (Krajewska M et al., 1996), and Survivin (Altieri 
DC, 2003b).  Survivin, an inhibitor-of-apoptosis (IAP) protein family member, is 
associated with PCa development, progression, and drug resistance (Krajewska M et al., 
2003, Kishi H et al., 2004, Shariat SF et al., 2004, Koike H et al., 2008).  Recent 
evidence indicates that the overexpression of Survivin in PCa tumors is associated with 
poor prognosis and increased tumor recurrence (Nakahara T et al., 2007).  In contrast, it 
has also been shown that knockdown of survivin expression by siRNAs enhances the 
chemosensitivity of prostate cancer cells, reducing tumorigenicity (Shen et al., 2009). 
Traditionally, Survivin has been viewed as a cytoplasmic or nuclear protein.  
Recently, Survivin has been also shown to exist extracellularly, contained in small 
membrane bound vesicles known as exosomes (Khan S et al., 2009, Khan S et al., 2011).  
Exosomes are present in serum and urine and contain a wide range of proteins and RNAs 
and represent their tissue of origin making them a possible source or pool of novel PCa 
biomarkers (Duijvesz et al., 2011).  Consistent with Survivin’s association with 
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unfavorable clinicopathological parameters, extracellular trafficking of Survivin 
throughout the tumor microenvironment could be responsible for augmenting the 
aggressive status of a tumor while prohibiting or minimizing therapeutic results.  We 
have recently shown that exosome-bound Survivin protein can be secreted by cancer cells 
and be taken up by surrounding cells, producing a field effect that confers a general 
stress-survival phenotype . 
Our present study was designed to investigate the existence of exosomal Survivin 
in the plasma of PCa patients with a variety of PCa presentations and to compare its 
exosomal expression levels to those found in control volunteers with no diagnosis of 
cancer and to patients diagnosed with benign prostatic hyperplasia or BPH.  For the past 
25 years the Gleason grading system has been used to help evaluate the prognosis of men 
with prostate cancer.  Together with other parameters, prostate cancer has been staged as 
a means to predict prognosis and guide therapy (Fine & Epstein, 2008).  Extracellular 
Survivin was found highly expressed in the plasma exosomes of PCa patients exhibiting 
Gleason scores of 6 (low) and 9 (high), and in patients who had relapsed on 
chemotherapy.  However, there were no significant differences in Survivin levels 
between subjects with low or high Gleason scores.  In addition, though exosomes 
containing Survivin were found in the serum from patients with a diagnosis of BPH, the 
overall level was significantly lower than that found in the plasma from PCa patients.  
We believe that in addition to diagnostic markers, prognostic, predictive and therapeutic 
markers are needed to act as surrogate endpoints in forecasting disease severity, choosing 
treatments, and monitoring responses to therapies (Mikolajczyk et al., 2004, Fradet, 
2009, Fiorentino et al., 2010, Ploussard & de la Taille, 2010).  Our demonstration of 
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exosomal Survivin in the plasma of patient with newly diagnosed low-grade PCa 
provides a rationale for studies to investigate the utility of exosomal Survivin as an early, 
easily measured biomarker for PCa diagnosis.  Exosomal Survivin may also be studied as 
a biomarker to monitor treatment of subjects with advanced PCa. 
 
Results 
Plasma Levels of Survivin in Healthy Controls and PCa Patients 
Survivin was detectable in the plasma from all healthy control subjects and PCa 
patients.  The measurement results of plasma Survivin in normal healthy controls and 
PCa patients are shown in Figure 1A.  The mean plasma Survivin levels were 
significantly different between the healthy control subjects (61.5 pg/ml in controls 
[n=10]) and the different cancer patient groups (Gleason 6 = 401.7 pg/ml [n=10], Gleason 
9 =  375.2 pg/ml [n=10], and subjects resistant to the the chemotherapy agent Taxotere = 
410 pg/ml [n=8]; P< 0.05 for each comparison vs. control).  When the Survivin levels 
were compared among the three groups of PCa patients in two-way comparisons, none 
were significantly different from the others. 
 
Survivin Can Be Collected From Serum Taken From Healthy Controls, BPH and PCa 
Patients 
 Like what has been measured above in plasma, Survivin was also detectable in the 
serum from patients having no prior diagnosis of cancer as well as in patients having the 
diagnosis of benign prostatic hyperplasia (BPH) and those diagnosed with prostate cancer 
(PCa) (Figure 1B).  The mean serum Survivin levels were significantly (P<0.001) higher  
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Figure 1.  Quantification of Survivin levels in PCa plasma (A) and serum (B) samples by 
ELISA.  A. Survivin levels were measured in plasma derived from Gleason 6 (n=10), 
Gleason 9 (n=10), and Taxotere-resistant subjects (n=8).  B. Survivin levels were measured 
in serum derived from BPH (n=20), and PCa (n=19).  Comparisons were accomplished 
using MANOVA with normal healthy controls (n=10 and 6 respectively). (**, p<0.05, ***, 
p<0.001; statistically significant). 
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in the PCa subjects (150 pg/ml [n=19]) than in the serum processed from normal controls 
(59.7 pg/ml [n=6]) and from BPH patients (55 pg/ml [n=21]). 
 
Plasma and Serum Survivin in PCa Patients Exists in an Exosomal Pool 
We have previously demonstrated that cultured PCa cells release Survivin into the 
extracellular milieu within exosomes (Khan S et al., 2009).  These small, membrane-
vesicles are also known to occur in the plasma as well as serum of cancer patients 
(Mitchell et al., 2009, Koumangoye et al., 2011).  Exosomes were therefore collected by 
differential centrifugation, and quantitated using the acetylcholinesterase enzymatic 
assays as we and others have previously described (Johnstone, 2006, Khan S et al., 
2011).  The mean plasma exosome levels were significantly different between the healthy 
control subjects and the different cancer patients groups (P< 0.001) whereas significant 
differences in exosome quantity were not found among the PCa patient sample groups 
(Figure 2A). This was also the case when comparing the exosome quantities found in 
BPH and PCa samples to that of the healthy control subjects (Figure 2B).  Interestingly, 
there appears to be a measureable difference in Survivin and in exosomes depending 
upon the source as both Survivin and exosome quantities were higher when purified from 
plasma then when purified from serum. 
 
Plasma-Derived Exosomes Contain Survivin 
 Exosomes were characterized by immunoblotting for the amount of Survivin 
protein and Lysosomal-associated membrane protein 1 (LAMP1).  LAMP1 is a known 
exosome protein which is commonly used to ensure proper Western blot loading (Quah 
& O'Neill, 2005, Bhatnagar et al., 2007, Khan S et al., 2011).  Exosomes isolated from  
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Figure 2.  Exosomal contents in PCa patients plasma (A) and serum (B) samples by using 
the acetylcholinesterase activity assay.  A. Exosome levels were measured in plasma 
derived from Gleason 6 (n=10), Gleason 9 (n=10), and Taxotere-resistant subjects (n=8).  
B. Exosome levels were measured in serum derived from BPH (n=20), and PCa (n=19).  
Comparisons were accomplished using MANOVA with normal healthy controls (n=10 and 
6 respectively). (**, p<0.05, ***, p<0.001; statistically significant). 
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PCa patient plasma exhibited enhanced Survivin loads compared to exosomes isolated 
from controls (Figure 3).  Western blot analysis showed that little exosomal Survivin was 
detectable in plasma samples collected from six controls having no previous diagnosis of 
cancer in comparison to the exosome-specific protein Lamp1 (Figure 3A).  In contrast, 
exosomes isolated from all twenty pre-treatment PCa subjects contained high amounts of 
Survivin protein compared to LAMP1 protein levels (Figure 3B).  Interestingly, there 
was no significant difference in exosomal Survivin content between patients with 
Gleason 6 PCa and those with Gleason 9 PCa (Figure 3C) when normalized against 
Lamp1 (p<0.05). 
 
Differential Expression of Survivin Exists in BPH and PCa-Derived Exosomes 
 As above, exosomes collected from BPH and PCa patient serums were 
characterized by immunoblotting for Survivin and LAMP1 protein (Figure 4A).  
Exosomes isolated from PCa and BPH patient serums exhibited enhanced Survivin loads 
compared to exosomes isolated from controls (Figure 4A, Figure 4B and Figure S1).  
Interestingly, though Survivin was detected in most and elevated in certain BPH patients, 
its overall level was significantly less than that found in PCa and there was no significant 
difference measured between BPH and control patient serums (Figure 4B). 
 
PCa Patients with Disease Progression Express High Levels of Exosomal Survivin 
 Lastly, we evaluated exosomes collected from PCa patients who experienced 
disease progression while on treatment with chemotherapy.  Like in our Gleason patient 
exosomes, Western blotting showed Survivin protein levels (Figure 5A) were markedly 
higher when compared to cancer-free control subjects, which was confirmed to be  
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Figure 3.  Western Blot Analysis of exosomal Survivin in untreated PCa plasmas.  A.  
Antibodies for Survivin and Lamp1 were used for Western blotting of control patient-
purified exosomal protein.  B.  Both Survivin and Lamp1 antibodies were detected in the 
Western Blotting of exosomes-derived from Gleason 6 and Gleason 9.  C. Proportion 
analysis of Survivin density to Lamp1 density were shown in both Gleason 6, and Gleason 
9 with normal healthy controls (**, p<0.05, statistically significant) with no significance 
recorded between Gleason 6 and Gleason 9 plasma-derived exosomes. 
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Figure 4.  Western Blot Analysis of exosomal Survivin in normal control, BPH and 
untreated PCa serum samples.  A.  Antibodies for Survivin and Lamp1 were used for 
Western blotting of patient-purified exosomal protein.  B. Proportion analysis of Survivin 
density to Lamp1 density were shown in both BPH and PCa with normal healthy controls 
(**, p<0.05, ***, p<0.001; statistically significant) with no significance recorded between 
normal controls and BPH. 
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Figure 5.  Western Blot Analysis of exosomal Survivin and Lamp1 in Taxotere-resistant 
PCa patients.  A.  Survivin and Lamp1 antibodies were shown positive.  B.  Densitometric 
analysis of Survivin/Lamp1 expression in a healthy control (normal) and chemoresistance 
(CR) cases (**, p<0.05, statistically significant).  
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Figure S1.  Western Blot Analysis of exosomal Survivin in normal control, BPH and 
untreated PCa serum samples.  Antibodies for Survivin and Lamp1 were used for Western 
blotting of patient-purified exosomal protein. 
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significant after densitometric analysis (Figure 5B).  
 
Clinical and Pathological Characteristics 
 Pretreatment data regarding initial plasma Survivin and PSA levels and Gleason 
scores were acquired for the patients studied.  These pathological characteristics are 
detailed in Tables 1-4.  In all, eight cases of prostate cancer recurrence after conventional 
treatment, ten cases of Gleason 6, ten cases of Gleason 9,  (Table 1); and ten control 
cases (Table 2) were collected with plasmas analyzed.  PSA from the plasma (clinical 
report) and from the ultracentrifuge-purified exosomes showed that though the protein 
concentrations were not identical, there was similarity in the trend of plasma to plasma-
derived exosome PSA values.  Importantly, Survivin amounts though significantly less in 
the exosomes were more consistent across the patients evaluated, and given the 
sensitivity of the ELISA, picograms for Survivin compared to nanograms for the PSA, is 
more accurate. 
 Further studies using sera instead of plasma were performed on six controls, twenty 
BPH cases (Table 3) and 19 additional PCa cases (Table 4).  Like before, ELISA results 
from Survivin provided a more sensitive and stable quantitation than did the ELISA for 
PSA.  Quantitation from the sera of BPH patients showed an average of 52.9 pg/ml 
Survivin and 1.3 ng/ml PSA.  In comparison, when evaluated from PCa patients, Survivin 
averaged 149 pg/ml and PSA averaged 0.3 ng/ml (Tables 3 and 4).  BPH numbers for 
both Survivin and PSA are nearly 3 fold lower than in the PCa patient sera.  
Unfortunately, purchased BPH samples did not come with the clinical PSA ELISA 
quantities that we have from the PCa cases (Table 3). 
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Correlations of Survivin with PSA 
 Of the patient’s plasma/serum samples evaluated for Survivin, all samples 
(Gleason 6, Gleason 9, recurrence, or PCa samples) exhibited greater than 100 pg/mL 
Survivin (Table 5).  In contrast, only 60% of Gleason 6, 80% of Gleason 9 plasmas and 
84% of PCa sera had a PSA of greater than 4 ng/mL.  Recurrent patient plasmas all had 
greater than 4 ng/mL.  In control plasmas and BPH sera, no sample had a Survivin 
concentration greater than 100 pg/mL and no PSA concentration greater than 4 ng/mL 
(Table 5). 
 
Discussion 
Prostate carcinoma resists apoptosis with altered expression of both pro- and on 
Survivin, a multifunctional member of the inhibitor of apoptosis (IAP) gene family that 
counteracts cell death and controls mitotic progression.  Selective overexpression of 
Survivin has been associated with higher tumor grade, advanced disease stage, rapid 
tumor progression, short patient survival, and resistance to therapy in patients with 
various malignancies (Krajewska M et al., 2003, Kishi H et al., 2004, Koike H et al., 
2008). 
 Survivin exists in a number of subcellular locations such as the mitochondria, 
cytoplasm, and nucleus.  Recently it has also been found in the extracellular space (Khan 
S et al., 2009, Khan S et al., 2011).  We have shown that extracellular Survivin exists in 
multimolecular complexes which include heat shock proteins (Khan S et al., 2011).   
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Table 1.  Survivin ELISA and PSA levels of plasma from Chemo-resistance, Gleason 
6, and Gleason 9 patients are shown. 
 
Chemo-Resistance 
Patients 
ID# 
Figure 
ID# 
Survivin 
ELISA(pg/mL) 
PSA* 
(ng/mL) Exosomal PSA (ng/mL) 
006 CR1 503+/-81.9 110 62.28+/-1.2 
009 CR2 382+/-29.1 51.5 38.13+/-1.5 
010 CR3 435+/-32.4 15.8 4.37+/-7 
012 CR4 305+/-19.9 55.4 304.85+/-76.9 
013 CR5 413+/-141.5 970 443.25+/- 
002a N/A 258+/-5.2 235 79.84+/-11.7 
002b N/A 246.6+/-183 8.9 1.32+/-0.4 
007 N/A 327+/-10.8 62.9 31.91+/-6.6 
Gleason 6 
028 1 332+/-15.3 3 2.43+/-0 
044 2 328+/-54 2.4 2.90+/-0.2 
061 3 330+/-34 5.8 0+/-1.1 
066 4 332+/-4.5 8.1 6.10+/-0.5 
077 5 313+/-26.8 4.4 5.63+/-0.7 
085 6 1366.5+/-82.7 4 1.30+/-0.3 
089 7 311+/-7.5 2.9 4.08+/-0.9 
093 8 306+/-25.4 4.1 0.39+/-0 
101 9 317+/-30.6 3.1 0.93+/-0 
117 10 311+/-22.9 7 0+/-0.7 
Gleason 9 
270 1 386+/-27.6 11 0.21+/-0.1 
367 2 336+/-15.8 6.7 0.42+/-3.4 
381 3 393+/-48.1 4.2 0+/-0.9 
396 4 348+/-13.7 3.1 2.67+/-0 
401 5 287+/-9.1 4.7 4.33+/-18 
410 6 603+/-19.6 9.3 2.14+/-0 
440 7 301+/-19.9 9.3 2.08+/-0.3 
456 8 306+/-18.2 5.54 0.61+/-0.3 
474 9 417+/-121.7 3.65.1 0.36+/-0.2 
517 10 375+/-7.9 17.8 0+/-1.4 
N/A: Not available  *Clinical PSA values 
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Table 2.  Survivin ELISA and PSA levels of plasma from controls 
with no diagnosis of cancer. 
 
Patients 
ID# Figure ID# Survivin (pg/mL) Exosome PSA (ng/mL) 
OPN 118 N1 67.5+/-0 0+/-0 
OPN 119 N2 65+/-14.9 0+/-0.2 
OPN 120 N3 75+/-7 0+/-0.3 
OPN 121 N4 60+/-7 0+/-0.2 
OPN 122 N5 45.75+/-1.4 0+/-1.0 
OPN 123 N6 60+/-7.1 0+/-1.5 
OPN 124 N7 67.5+/-0 0+/-.5 
OPN 125 N8 71.6+/-10 0+/-1.5 
OPN 126 N9 35+/-14 0+/-.5 
OPN 127 N10 67.5+/-0 2.17+/-0.4 
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Table 3.  Survivin ELISA and PSA levels of Sera from BPH patients are shown. 
 
Patients ID# Figure ID# Survivin ELISA(pg/mL) 
Exosomal PSA 
(ng/mL) 
VCT08 1 44.5+/-4.94 0.955+/- 
G918 2 46.5+/-0.7 0 
4PHH 3 45+/-5.6 1.955 
OSWG3 4 46+/-7 2.17 
XHZN 5 64.5+/-6.36 0 
87LUH 6 25+/-35.3 2.67 
CC51Y 7 24.5+/-34.64 2.305 
XHWCG 8 45.5+/-0.7 1.88 
IOAYY 9 49.5+/-0.7 0 
ZUQ1B 10 76.5+/-21.2 2.275 
L8K8F 11 54.5+/-2.12 2.745 
WBZVY 12 52.5+/-7.7 2.5 
X3GDZ 13 49+/-1.14 1.955 
9UXFW 14 89+/-2.8 0 
JCO8M 15 55.5+/-2.12 2.35 
XWKEL 16 53+/-11.3 0 
H2GY6 17 45.5+/-4.9 2.035 
PPAQH 18 54.5+/-12 0 
AU4AD 19 66.5+/-3.5 0 
DXCOB 20 70.5+/-0.7 0 
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Table 4.  Survivin ELISA and PSA levels of Sera from Prostate Cancer patients. 
 
Patients 
ID# Figure ID# 
Survivin 
ELISA(pg/mL) 
PSA 
(ng/mL) 
Exosomal PSA 
(ng/mL) 
642 1 140.1+/-0.34 6.2 0 
6227 2 147.13+/-4.4 3.29 0 
6636 3 154.21+/-7.24 4.5 0 
3918 4 142.93+/-1.88 5.2 0 
3960 5 140+/-0.03 13.5 0 
2060 6 139+/-1.25 10.6 0 
304 7 133.13+/-7 5.3 0 
624 8 123.4+/-7.39 8.8 0 
286 9 157.16+/-2.44 2.73 0 
2828 10 155.75+/-5.7 3.9 0 
14739 11 154.58+/-2.71 6.82 0 
13077 12 155.7+/-2.1 7.1 1.73 
6129 13 183+/-19.79 5.4 0 
9508 14 179+/-26.87 9.4 1.835 
14824 15 135.5+/-7 7 0 
13406 16 146+/-2.82 8.8 2.335 
9594 17 145+/-2.12 6.56 0 
5117 18 149+/-7 42 0 
69 19 146+/-5.6 58 0 
*Clinical PSA Values 
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Table 5. Correlation of Survivin and PSA levels from Plasma. 
 
Patients Survivin (pg/mL) 
PSA 
(ng/mL) 
Normal <100 (n=10) (100%) >100 (n=0) (0%) 
<4 (n=10) (100%) 
>4 (n=0) (0%) 
Gleason 6 <100 (n=0) (0%) >100 (n=10) (100%) 
<4 (n=4) (40%) 
>4 (n=6) (60%) 
Gleason 9 <100 (n=0) (0%) >100 (n=10) (100%) 
<4 (n=2) (20%) 
>4 (n=8) (80%) 
Recurrences <100 (n=0) (0%) >100 (n=8) (100%) 
<4 (n=0) (0%) 
>4 (n=10) (100%) 
BPH <100 (n=20) (100%) >100 (n=0)   (0%) 
<4 (n=20) (100%) 
>4 (n=0)  (0%) 
PCA <100 (n=0) (0%) >100 (n=19) (100%) 
<4 (n=3) (16%) 
>4 (n=16) (84%) 
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Furthermore, we have also shown that these complexes reside in or on exosomes, and that 
cancer treatment can enhance release of such exosomes from cancer cells (Khan S et al., 
2011).  Extracellular Survivin is able to mediate a pro-survival field effect through its 
secretion by cancer cells and uptake by surrounding normal and transformed cells (Khan 
S et al., 2009).  Linking extracellular Survivin’s ability to enhance cellular proliferation, 
survival and tumor cell invasion with a membrane-protective trafficking modality 
provides additional support for the hypothesis that Survivin plays a pivotal role in the 
pathobiology of cancer cell growth and protection from therapeutic interventions.   
Several previous studies have examined the plasma levels of Survivin in cancer 
patients (Sugahara et al., 2004, El-Attar et al., 2010).  In adult T-cell leukemia and the 
supernatants from in vitro cultures of solid-tumor cells, the levels of Survivin protein was 
low compared to the cellular Survivin protein and mRNA levels (Sugahara et al., 2004).  
This finding resulted in the conclusion that Survivin protein levels in plasma do not 
reflect cellular Survivin levels.  Furthermore, Survivin plasma levels were evaluated 
compared to alpha fetoprotein (AFP) in patients with chronic hepatitis C viral infection 
(HCV) with and without hepatocellular carcinoma (HCC) (El-Attar et al., 2010).  Though 
not concluded to be as reliable in these studies as AFP, Survivin levels were determined 
to be measurable and significant in patients suffering with HCV and measurable but not 
significant in those with HCC.  Though not entirely clear, these results could be 
explained by the finding that HCV-infected HCC cells became more resistant to cell 
death and thus Survivin release compared to control or HCV-infected cells alone (El-
Attar et al., 2010). 
The prostate specific antigen (PSA) assay has been controversially utilized in 
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prostate cancer screening though initially it was envisioned as a tool for evaluating 
treatment response (Croswell et al., 2011).  Its use as a screening tool was driven by both 
the US prostate cancer burden and a need to detect its presence at a time that would allow 
for curative treatment to begin.  Unfortunately, its use is believed to have led to both over 
diagnosis and overtreatment and hence the urgent need for novel biomarkers to be found 
to supplement PSA for management and treatment (Mazzola et al., 2011).  Exosomal 
Survivin measurements may provide another plasma-based assay for the presence of PCa.  
In the present study, we have identified for the first time that exosomes containing 
Survivin can be purified from plasma collected from patients with a diagnosis of PCa.  
Although there was little difference in exosome quantity, exosomal Survivin levels were 
higher in exosomes purified from PCa patients than from the sera of normal controls.  In 
addition, in this study and that performed by others (Sugahara et al., 2004, El-Attar et al., 
2010), plasma-quantitated Survivin in samples taken from patients with no confirmed 
cancer diagnosis, also had reduced Survivin levels compared to PCa patient sera.  The 
source of this exosomal Survivin pool, though unclear, may originate in immune cells 
(Iero et al., 2008) such as lymphocytes (Clayton et al., 2005), monocytes (Valenti et al., 
2007) and dendritic cells (Quah & O'Neill, 2005), all Survivin containing cells (Fukuda 
& Pelus, 2006) which have been shown to release exosomes.  Survivin expression is 
associated with established features of biologically aggressive prostate carcinoma, such 
as higher final Gleason score and metastasis to regional lymph nodes (Shariat SF et al., 
2004).  In our study we found that patients who had failed treatment with Taxotere had 
elevated levels of exosomal Survivin.  In addition, and of special interest, we found that 
patients presenting with either mid (Gleason 6) or high (Gleason 9) Gleason scores 
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exhibited higher exosomal Survivin levels with no significant difference in Survivin 
content between them.  Our findings, though more robust in the plasma we studied appear 
in agreement with what has been found with urine, tumor exosomes and PSA (Mitchell et 
al., 2009).  In these studies, urine exosome PSA is described as present in 20 of 24 PCa 
specimens while in our hands, tumor exosome Survivin is found in 47 of 47 specimens.  
Whether or not cancer treatment will affect tumor exosome Survivin levels has yet to be 
evaluated. 
In this current study, we provide compelling evidence that circulating Survivin 
may be a useful diagnostic and prognostic marker for human PCa.  Our results indicate 
that Survivin, analyzed directly from serum/plasma or from serum/plasma-derived 
exosomes, was lower in patients with BPH and healthy controls than in men with PCa.  
Survivin levels did not change, being consistently high, with regard to Gleason score and 
patients having recurrence, suggesting that Survivin levels could be used for early 
detection and could perhaps one day more accurately differentiate BPH from PCa.  
Comparing patients with and without tumors, but both having high PSA values will also 
be an important next step, as in our hands all the BPH samples we have acquired have 
relatively non-cancer PSA values (Williams & Naz, 2010). 
The role of exosomal Survivin is still unknown.  It is possible that a therapy-
stressed, cellular release of exosomes containing Survivin and other antiapoptotic 
proteins, RNAs or miRNAs is performed as a final attempt to protect themselves from the 
stress that exists within the tumor microenvironment.  Larger studies with more events 
and longer follow-up will be required to develop a more definitive statement regarding 
the association of Survivin expression in exosomes or in the tumor microenvironment 
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with prostate carcinoma progression and as importantly, metastasis and survival.  These 
findings will provide a rationale for further evaluation of exosomal Survivin and its role 
in resistance to androgen-based therapy in prostate carcinoma and raise the possibility of 
targeted combination therapy for advanced prostate cancer. 
Our finding that Survivin, a unique human inhibitor of apoptosis (IAP), has 
intercellular transport and signaling capabilities is significant.  Consistent with Survivin’s 
association with unfavorable clinicopathological parameters, trafficking Survivin 
throughout the tumor microenvironment can drive the aggressive status of the tumor, 
prohibiting or minimizing therapeutic results.  In our current work we show that though 
the overall number of exosomes being shed into patient plasma does not significantly 
change during the development of cancer, the level of Survivin in those exosomes 
increases significantly.  Importantly, progression from mid- to late-stage does not drive 
an appreciable Survivin increase indicating that Survivin may prove useful as a 
biomarker for earlier detection of prostate cancer.  Indeed, Survivin-based testing, 
performed on tumor-exosomes, will allow molecular-based diagnosis that in time may 
also aid in therapy decisions and disease response surveillance leading to better 
management of prostate cancer. 
 
Materials and Methods 
Patient Plasma and Serum 
Plasma samples were collected from ten healthy male volunteers, and twenty-
eight PCa patients.  Plasma from twenty PCa subjects was obtained from the specimen 
bank of the SPECS consortium which is an observational clinical trial which utilizes 
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prostate tissue and clinical values obtained by informed consent to derive gene signatures 
predictive of outcome at the time of diagnosis.  SPECS is directed by Dr. Dan Mercola 
from the University of California, Irvine.  Samples were pre-prostatectomy plasma 
randomly selected from ten low-grade PCa cases (Gleason 6) and ten high-grade PCa 
cases (Gleason 9).  In addition, plasma from eight advanced-disease PCa patients 
participating in a second-line chemotherapy trial was also collected.  These patients had 
failed chemotherapy with Taxotere. Nineteen serum samples were collected from PCa 
patients and six controls through the San Manuel Band of Mission Indians Biospecimen 
Laboratory at Loma Linda Universities Cancer Center.  Twenty BPH samples were 
purchased from Bioserve Biotechnologies, Beltsville, MD.  Bioserve Biotechnologies as 
provider of these samples is covered as defined in the HIPPA Act of 1996 as is providing 
them to us with a limited data set of protected health information. 
Blood was collected in vacuum tubes containing sodium heparin.  The tubes were 
centrifuged at 2000g x 7 minutes, and the plasma was then removed and aliquoted for 
storage at -80qC.  All samples were obtained in the course of IRB-approved studies, 
following the documentation of informed consent in accordance with university policy at 
both Loma Linda University and the University of California at Irvine. 
 
Human Survivin Immunoassay 
Whole plasma samples were subjected to a commercially available human 
Survivin Immunoassay (R&D systems, Minneapolis, MN) using the manufacturer’s 
instructions in order to quantitate Survivin concentrations. 
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Exosome Isolation 
Plasma microvesicles were isolated as previously described, with minor 
modifications (Caby MP et al., 2005).  Thawed, cryopreserved plasma (2 ml) was 
centrifuged for 30 min at 500 x g, 45 min at 12,000 x g and 18 h at 110,000 x g.  Pellets 
were resuspended in a large volume of PBS, filtered through a 0.22-μm filter (Millipore, 
Billerica, MA) and centrifuged at 110,000 x g for 1 h.  Microvesicle pellets were washed 
once in a large volume of PBS, centrifuged at 110,000 x g for 1 h and re-suspended in 
50–200 ml of PBS.  The amount of 110,000 x g pellet proteins recovered was measured 
using the BCA protein assay kit (Pierce, Rockford, IL).  Exosomes were used as fresh 
preparations for immunoblotting or were conserved at -80 C for later use.  For serum 
samples, the commercially available ExoQuick (SBI, Mountain View, CA) was 
employed as described by the vendor.  Briefly, 100 μL of serum was incubated with 100 
PL of ExoQuick solution followed by a 2 hr incubation at 4 °C followed by 
centrifugation at 1500 x g for 30 minutes.  After centrifugation the exosomes appear as a 
beige or white pellet at the bottom of the vessel which is then reconstituted with 500 μL 
of dH2O. 
 
Exosome Quantification 
To quantify the amount of exosomes released, we assessed the activity of 
acetylcholinesterase, an enzyme that is associated with these vesicles.  
Acetylcholinesterase activity was assessed as described by Savina et al. (Savina A et al., 
2003).  Briefly, 40 μl of the exosome fraction was suspended in 110 μl of PBS.  37.5 ml 
of this PBS-diluted exosome fraction was then added to individual wells on a 96-well 
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flat-bottomed microplate.  1.25 mM acetylthiocholine and 0.1 mM 5,50-dithiobis(2-
nitrobenzoic acid) were then added to exosome fractions in a final volume of 300 μl, and 
the change in absorbance at 412 nm was monitored every 5 min for 30 min.  
 
Human PSA Immunoassay 
Isolated exosomes from patients` plasma were subjected to human Prostate 
Specific Antigen (PSA) using a PSA Immunoassay (American Research Products, Inc., 
Waltham, MA, USA) kit following the manufacturer’s instructions in order to quantitate 
PSA concentrations in exosomes. 
 
Western Blot Analysis 
For Western blot analysis, cells or exosomal preparations were lysed using lysis 
buffer (50 mM Tris (pH 7.5), 1% NP40, 0.25% DOC, 150 mM NaCl2, 1 mM PMSF, 10 
μg/ml Aprotinin/ leupeptin/pepstatin, 20 mM NaF, 0.2 mM EGTA, 1 mM EDTA (pH 
8.0), H2O).  For protein concentrations the BCA assay (Pierce, Rockford, IL) was used.  
Proteins from exosomes (20–40 μg) were separated using 12% Bis–Tris polyacrylamide 
gels, transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA) 
and probed using the following antibodies: mouse monoclonal anti-LAMP1 (Abcam, 
Cambridge, MA), and rabbit polyclonal anti-Survivin (Novus, Littleton, CO).  Secondary 
antibodies (IR-Dye conjugated) were goat anti-rabbit and goat anti-mouse 
immunoglobulin (LICOR, Lincoln, Nebraska).  Immunoreactive bands were detected 
using the Odyssey Imaging System (LICOR, Lincoln, Nebraska) and quantified using 
ImageQuant software. 
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Statistical Analysis 
Multiple comparisons among different groups were calculated by using Multiple 
Analysis of Variance (MANOVA).  Student t-test (two-tailed) was used to evaluate the 
significance of changes between control groups and experimental groups.  Probability 
values P<0.05 were considered statistically significant. 
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Abstract 
 Prostate cancer (PCa) remains the most frequently diagnosed male malignancy in 
Western countries and the second most common cause of male cancer death in the United 
States. The relatively elevated PCa incidence and mortality among African American 
men makes this cancer type a challenging health disparity disease. To increase the chance 
for successful treatment, earlier detection and prediction of tumor aggressiveness will be 
important and need to be resolved. This study demonstrates that small membrane-bound 
vesicles shed from the tumor called exosomes contain ethnically and tumor-specific 
biomarkers, and could be exploited for their diagnostic and therapeutic potential.  
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Introduction 
Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer in men 
and the second leading cause of male cancer deaths in the United States, accounting for 
233,000 new cases and 29,480 deaths in 2014 (Siegel et al., 2014).  The incidence of the 
disease has an uneven geographic distribution with the highest rates recorded in 
Australia, North and Western Europe and the United States (Jemal et al., 2011).  The 
incidence and mortality of the disease is disproportionately high among African 
American (AA) men compared to other ethnicities in the United States (Aizer et al., 
2014).  An interesting note is that the disease incidence appears to be lower among Black 
men in Africa, although this has been attributed to the lack of adequate and sufficient 
statistics from this region of the world (Tindall et al., 2014).  
While the basis for PCa health disparities is not well understood, evidence points 
to the interplay between socioeconomic, environmental, and biologic/genetic factors 
(Aizer et al., 2014). A number of risk factors for PCa have been examined in the 
literature including chronic inflammation of the prostate (infectious and non-infectious), 
hormonal factors (elevated testosterone, leptin etc.), smoking, dietary and genetic factors; 
among others.  Smith et al., described the link between the susceptibility gene HPC-1 
(Hereditary PCa) and an increased risk of developing PCa, especially in younger patients 
(Smith et al., 2011).  Overall, PCa is believed to be a disease of multifactorial origin. 
Prostate Specific Antigen (PSA) combined with a digital rectal exam has 
remained the standard of screening for PCa for the past two to three decades.  PSA was 
first described as a marker for human semen in forensics but it was subsequently 
demonstrated in the serum of men with prostate disease (Verma et al., 2014).  The test 
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was however intended for surveillance of diagnosed PCa patients.  There was a sharp rise 
in newly diagnosed cases in the early 1990’s attributed to the introduction of PSA as an 
FDA-approved screening test for PCa.  Coincident with this increase in the number of 
new cases diagnosed was a pathologic migration toward a more favorable (early disease) 
stage at diagnosis (Bryant & Lilja, 2014, Darwish-Yassine et al., 2014).  Non-palpable 
PCa (and therefore perhaps clinically treatable disease) now accounts for 70-80% of 
newly diagnosed cases (Kardasevic & Delic-Redzepagic, 2014, Powell et al., 2014).  
This may at least in part explain why the combined 5 and 10 year survival for all stages 
of PCa is currently at 99% and 91% respectively. The true clinical value/advantage of 
using serum PSA as a screening test has been recently called into question.  While the use 
of this test has increased the proportion of patients with lower tumor stage at the time of 
diagnosis, its value is still debated because of its limitations.  These limitations include 
the cut-off PSA value of 4.0 ng/ml which fails to detect a significant number of prostate 
tumors; PSA screening has not been demonstrated to improve health outcomes, 
particularly in older men; PSA is not specific for PCa since its levels can be elevated in 
patients with benign prostatic hyperplasia (BPH) and prostatitis, leading to a false-
positive finding of up to 60-80% of prostate biopsies; and obesity lowers PSA levels, 
which in theory could lead to delayed detection of PCa and worse clinical outcome 
(Bradley et al., 2013).  Moreover, the lack of specificity of PSA as a screening tool has 
also led to many possibly unnecessary diagnostic (biopsies) and therapeutic procedures.  
The conclusions from the European Trial of PCa screening was that 1410 
screenings/biopsies had to be performed and 48 additional cases treated in order to 
prevent one death from PCa (Loeb et al., 2011).  It should be noted, however, that most 
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of the information available on the efficacy of the PSA test is based on studies of men of 
European descent and that despite its limitations, PSA screening is still highly 
recommended for AA men ages 45 and above (Faraday et al., 2009). The limitations of 
the PSA test demand increasing the efforts to identify novel biomarkers that will 
supplement this test and enhance early PCa detection, management and therapeutic 
response.  For this purpose we have initiated the evaluation of small membrane-bound 
vesicles called exosomes derived from PCa patients from different ethnicities for the 
possibility that they may contain yet undiscovered biomarkers.  Potentially, these 
biomarkers could be tailored for early PCa detection and management in AA men, with 
the ultimate goal of reducing or eliminating PCa health disparities. 
Recent studies have shown that tumor-derived exosomes are key modulators of 
cell to cell and cell to extracellular communication within the tumor microenvironment 
(Johnstone, 2006).  Exosomes play an important part in this communication due to their 
ability to transport cancer-promoting material such as protein, RNA and miRNA 
(Johnstone, 2006, Khan S et al., 2011, Khan et al., 2015).  In order to successfully treat 
cancer, it will be crucial to develop therapeutic strategies that not only target tumor cells 
but also the mediators within the tumor microenvironment that modulated many aspects 
of the etiology of this disease (Aspe et al., 2014, Asuncion Valenzuela et al., 2015, 
Valenzuela et al., 2015). However, enhanced treatment capabilities are the direct result of 
earlier detection which will depend significantly on the early discovery of biomarkers 
shed by these tumors (Properzi et al., 2013). 
Exosomes are present in serum, plasma and urine and contain a wide range of 
proteins and RNAs, representing their tissue of origin thus making them a possible source 
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or pool of novel PCa biomarkers (Duijvesz et al., 2011).  Our present study was designed 
to profile the exosomal proteins from the plasma of ethnically diverse PCa patients and 
control individuals with no diagnosis of PCa, and to compare these exosomal profiles 
between the different ethnic groups. We believe that in addition to diagnostic markers, 
prognostic, predictive and therapeutic markers are needed to act as surrogate endpoints in 
forecasting disease severity, choosing appropriate treatment modalities, and monitoring 
responses to therapies (Mikolajczyk et al., 2004, Fradet, 2009, Fiorentino et al., 2010, 
Ploussard & de la Taille, 2010).  Our previous demonstration of exosomal Survivin, an 
inhibitor of apoptosis and indicator of cancer severity, in the plasma of patients with 
newly diagnosed PCa (Khan et al., 2012) provided a rationale for studies to investigate 
the utility of exosomal content as a source of early, easily measured PCa biomarkers in 
ethnically diverse populations. Here we present our initial results in this effort. 
 
Materials and Methods 
Patient Plasma 
Plasma samples were collected from 9 healthy male volunteers, and 12 PCa patients 
(Table I).  These 12 patients self defined themselves as AA (n=4), Caucasian (n=4) and 
Hispanic (n=4).  Blood was collected in vacuum tubes containing sodium heparin.  The 
tubes were centrifuged at 2000 x g for 7 minutes, and the plasma was then removed and 
aliquoted for storage at -80qC.  All samples were obtained in the course of IRB-approved 
studies, following the documentation of informed consent in accordance with Loma 
Linda University policies. 
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Exosome Isolation 
For plasma microvesicle samples, the commercially available ExoQuick (SBI, 
Mountain View, CA) was employed as described by the vendor.  Briefly, 100 μl of 
plasma was incubated  
with 100 PL of ExoQuick solution followed by a 2 hr incubation at 4 °C followed by 
centrifugation at 1500 x g for 30 minutes.  After centrifugation the exosomes appear as a 
beige or white pellet at the bottom of the vessel which is then reconstituted with 500 μl of 
dH2O (Caby MP et al., 2005). 
 
Exosome Quantification 
To quantify the amount of exosomes released, we assessed the activity of 
acetylcholinesterase, an enzyme that is associated with these vesicles (Savina A et al., 
2003).  Acetylcholinesterase activity was assessed as described by Savina et al. (Savina A 
et al., 2003).  Briefly, 40 μl of the exosome fraction was suspended in 110 μl of PBS.  
37.5 ml of this PBS-diluted exosome fraction was then added to individual wells on a 96-
well flat-bottomed microplate.  1.25 mM acetylthiocholine and 0.1 mM 5,50-dithiobis(2-
nitrobenzoic acid) were then added to exosome fractions in a final volume of 300 μl, and 
the change in absorbance at 412 nm was monitored every 5 min for 30 min.  
 
Protein Separation 
For protein analysis, exosomal preparations were lysed using lysis buffer (50 mM 
Tris (pH 7.5), 1% NP40, 0.25% DOC, 150 mM NaCl2, 1 mM PMSF, 10 μg/ml Aprotinin/ 
leupeptin/pepstatin, 20 mM NaF, 0.2 mM EGTA, 1 mM EDTA (pH 8.0), H2O).  For 
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protein concentrations the BCA assay (Pierce, Rockford, IL) was used.  Proteins from 
exosomes (20–40 μg) were separated using 12% Bis–Tris polyacrylamide gels. 
 
In-Gel Trypsin Digestion and MS 
Protein bands were excised manually and washed with 50% (v/v) methanol and 
5% (v/v) acetic acid. The gel pieces were then dehydrated in acetonitrile and dried in a 
SpeedVac concentrator (Savant, Farmingdale, NY). Proteins were reduced using 10 mM 
dithiothreitol (DTT) in 100 mM ammonium bicarbonate for 30 min at room temperature. 
The DTT solution was removed and the proteins were alkylated for 30 min at room 
temperature using 100 mM iodoacetamide after which the gel pieces were dehydrated as 
before. Gel pieces were rehydrated in 100 mM ammonium bicarbonate and then 
dehydrated and dried as previously described. Proteins were tryptically digested using 
MS grade trypsin (Promega, Madison, WI), added at a final concentration of 20 ng/Pl to 
fully cover the gel pieces. Digestion was performed at 37 °C overnight. Peptides were 
recovered with 30 Pl, 50% (v/v) acetonitrile and 5% (v/v) formic acid twice. All 
supernatants were pooled and dried in a SpeedVac concentrator for 1 hr.  
Tryptic peptides were analyzed on a ThermoFinnigan LCQ Deca XP system that 
includes a surveyor HPLC and a PicoView 500 (New Objective, Woburn, MA) for 
performing nanoflow electrospray ionization. The flow of the surveyor HPLC pump was 
split to achieve a 200–300 nanoliter/min flow exiting a PicoFrit column (New Objective) 
packed with BioBasic C18 beads (10 cm, 5 l m, 300 A°). Samples were loaded onto a 
Michrom Bioresources (Auburn, CA) cap-trap at 5 l l/min and washed with mobile phase 
A (aqueous 2% acetonitrile with 0.1% formic acid). Peptides were then eluted onto the 
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column and into the mass spectrometer using a gradient of 0–75% mobile phase B 
(aqueous 90% acetonitrile with 0.1% formic acid). The mass spectra acquisition was 
operated in the data dependent mode with one MSscan (300–1,500 m/z) and three 
MS/MS scans of the most intense ions in the MS scan. We used the Sequest algorithm 
implemented on the TurboSequest software package to identify proteins based on the 
MS/MS spectra. The resulting Sequest hits were filtered based on the charge state and 
Xcorr value to require Xcorr C 1.5, 2.0, and 2.5 for single, double, and triple charged 
ions, respectively. 
The MS/MS fragmentation spectra were searched against a current human protein 
database (March 2009) containing 37,391 reference sequences. The search algorithms 
Sequest (Eng et al., 1994), Mascot (Perkins et al., 1999), and X! TANDEM (Craig & 
Beavis, 2004), were used to identify peptides and proteins. The significance of identified 
peptides and proteins were determined using the Peptide-Prophet (Keller et al., 2002) and 
Protein-Prophet (Nesvizhskii et al., 2003), respectively, algorithms as implemented in 
Scaffold 2 (Proteome Software, Portland, OR). We included only peptides with a 
Scaffold score of C 95% (5% false discovery rate) in the results. 
 
Statistical Analysis 
Multiple comparisons among different groups were calculated using Multiple 
Analysis of Variance (MANOVA).  A Student t-test (two-tailed) was used to evaluate the 
significance of changes between control groups and experimental groups.  Probability 
values P<0.05 were considered statistically significant. 
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Results 
PCa Patients Exhibit Increased Exosome Numbers 
We have previously demonstrated that cultured PCa cells release exosomes into 
the extracellular milieu (Khan S et al., 2009).  These small, membrane-vesicles are also 
known to occur in the plasma as well as serum of cancer patients (Mitchell et al., 2009, 
Koumangoye et al., 2011, Khan et al., 2012).  Exosomes were therefore collected using 
ExoQuick, and quantitated using the acetylcholinesterase enzymatic assay as we and 
others have previously described (Johnstone, 2006, Khan S et al., 2011, Khan et al., 
2012).  The mean plasma exosome levels varied significantly between the healthy control 
subjects group and the different PCa patient groups (P< 0.001).  However, there was no 
significant difference in exosome quantity between the different PCa patient groups 
(Figure 1). 
 
Plasma-Derived Exosomes Contain Potential Biomarkers 
 Exosomes purified using ExoQuick from PCa patient plasma were characterized by 
mass spectrometry.  After the extraction from a preparative gel (Figure 2), proteins were 
identified by LC-MS.  The ten most abundant proteins identified were: Apolipoproteins, 
Pregnancy Zone Protein, Macroglobulins, Keratin, Albumin Precursors, Haptoglobin, 
Ceruloplasmins, Transferrin, Complement Proteins and Fibronectin (Table 2).  Exosomal 
proteins were next categorized for localization using Scaffold 2 software and found to 
have the majority of their proteins determined to be intracellular (57%) and extracellular 
(32%) with only 7% identified as cell membrane and 4% as indeterminate (Figure 3A).  
Intracellular proteins present in the exosomes were next annotated for distribution and 
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Figure 1.  Exosomal contents in PCa patients plasma samples by using the 
acetylcholinesterase activity assay.  Exosome levels were measured in plasma derived from 
subjects representing Hispanic, African American and Caucasian PCa patients and control 
collected from the three ethnic groups.  Exosome levels were measured in serum derived 
from 9 control, 4 Caucasian, 4 African American and 4 Hispanic subjects.  Comparisons 
were accomplished using MANOVA.  (ns = not significant; **, p<0.05, statistically 
significant). 
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Patients 
 
Figure 2. Exosomal proteins taken from PCa patients plasma were separated on a 4-12% 
gradient SDS gel and stained with Coomassie brilliant blue.  Gels are representative of 2 
individual gels ran, showing 4 individuals of each ethnicity (C-Caucasian, AA-African 
American, H-Hispanic, N-no PCa diagnosis). The major bands were analyzed by trypsin 
digestion and LC-MS/MS mass spectrometry. Molecular-weight markers in kilodaltons 
(Kda) are shown on the left. 
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found to be mostly cytosolic (45%) and nuclear (24%), with the remaining 31% spread as 
cytoskeletal (9%), Golgi (2%), ER (4%), mitochondrial (3%) and ubiquitous (13%) 
(Figure 3B). 
 
Proteomic Comparison Across Different Ethnicities 
 Exosome protein compositions were compared between those purified from 
individuals with no diagnosis of PCa (non-Ca) and those with PCa (Figure 4A).  The 
exosomes from the non-Ca individuals provided the identities of 145 proteins (74+71) 
while the exosomes collected from the PCa patients provided the identities of 184 
proteins (71+113).  Though there were 71 proteins found in common, we believe that the 
analysis of the 74 non-Ca- specific and 113 PCa-specific proteins that could lead to the 
discovery of a novel biomarkers, either a molecule which has become reduced as tumors 
develop, identified from the unique non-Ca samples, or proteins with enhanced 
expression as the tumor develops, identified from the unique PCa samples.  When 
comparing proteins identified from exosomes of our non-Ca volunteers to ethnicity-
specific- associated PCa exosome proteins, the attribute most striking is the reduced 
number of proteins held in common and the low number of proteins unique to each 
ethnicity.  The sum of the proteins from AA (82), Hispanic (149) and Caucasian (63) do 
not add to the number of unique proteins from PCa (113) as there are a number of 
common proteins found among these three ethnic groups. 
 Ethnicity-specific exosomal proteins were next investigated in order to define if any 
of the 184 PCa-specific proteins, shared amongst the different ethnic groups were held in 
common with all ethnicities, pairs of ethnicities, or definitive for a single ethnicity.  Any 
protein held in common would be a potential biomarker for PCa, while proteins that were  
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Figure 3. PCa exosome protein localization.  A. Exosomal proteins were categorized for 
primary localization and found to have the majority of their proteins determined to be 
intracellular and extracellular with only a small percentage of them in the cell membrane 
or indeterminate.  B. Intracellular proteins were next categorized as being cytosolic, 
nuclear, cytoskeletal, golgi, ER, mitochondrial and ubiquitous in their distribution. 
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Figure 4.  Exosomal protein enrichment was monitored in each sample by mass 
spectrometry.  A. Cancer changes were assessed by first comparing PCa (CA) to the no 
PCa (N) diagnosis control and then controls to each ethnicity specific exosomal proteome.  
B. Intra-ethnicity was assessed by simply comparing within the ethnic-specific exosomal 
proteomes.  Venn diagrams show the comparisons in terms of exosome proteomes.   
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only found in a specific ethnicity would be ideal as a putative biomarker for PCa in that 
ethnicity.  Figure 4B shows that there are 35 proteins held in common between the three 
ethnic groups studied (Table 3) and there are 2, 24 and 13 shared proteins in 
AA/Caucasian, AA/Hispanic and Caucasian/Hispanic respectively, that should be further 
evaluated (Table 4).  We also identified proteins that are unique, in our analysis, to each 
individual ethnicity represented (Table 5 and Supplemental Table I). 
 Among all of these putative biomarkers are proteins of specific interest because 
they have been previously described as cancer-associated proteins (Table 6).  These 
includes: DNA helicase homolog PIF1, Four and a Half LIM Domain 3, Glutathione S 
transferase omega 2, Maternal embryonic leucine zipper kinase, Iroquois homeobox 
protein 5, Leucine rich zipper containing 4, minichromosome maintenance complex 
component 5, Mitochondrial tumor suppressor 1 isoform 4, nasopharyngeal epithelium 
specific protein, Ubiquitin-like with PHD and ring finger domains, and Trinucleotide 
repeat containing 6B isoform 3. 
 
Discussion 
The PSA test has been controversially utilized in PCa screening though initially it 
was envisioned as a tool for evaluating treatment response.  Its use as a screening tool 
was driven by both the United States PCa burden and a need to detect its presence at an 
early stage that would allow for curative treatment.  Unfortunately, its use is believed to 
have led to both over diagnosis and over treatment, and there remains an urgent need for 
novel biomarkers to be found to supplement PSA for early PCa detection, management, 
and treatment (Mazzola et al., 2011).  Recent efforts in PCa biomarker discovery and   
89 
 
  
90 
 
  
91 
 
  
92 
 
  
93 
 
 
94 
evaluation remain scarce and those that have been published describe proteins that though 
perhaps tumor specific, continue to show little specificity for PCa or require invasive or 
surgical procedures (Welsh et al., 2003, Lin et al., 2013). 
 The goal of this work was to further evaluate clinical samples of PCa taken from 
patients representing AA, Caucasian and Hispanic ethnicities for potential biomarkers of 
tumor definition and aggressiveness.  Collecting blood samples or a relatively non-
invasive “liquid biopsy” could provide clinicians with a superior diagnostic and 
therapeutic effectiveness-defining tool.  Analyzing the secretome, or the secreted 
biomolecules, from the developing tumor could more rapidly pinpoint the type of cancer 
and best practice for treatment. Here we analyzed microvesicles called exosomes which 
are ubiquitously released into the serum/plasma during tumorigenesis and have been 
shown to be specifically enhanced in the serum of PCa patients compared to their 
representative controls (Khan et al., 2012).  Furthermore, recent studies have 
demonstrated the importance of exosomal proteins in cancer cell function with a 
particular interest paid to their role in tumorigenesis (Khan S et al., 2009, Park et al., 
2012, Demory Beckler et al., 2013, Ji et al., 2013).  Our own recent work has defined the 
role of the inhibitor of apoptosis protein Survivin, released in tumor exosomes, in cellular 
proliferation, invasiveness and resistance to apoptosis (Khan S et al., 2009, Khan S et al., 
2011).  By comparing the secretome of PCa patients representing various ethnic groups, 
we may also gain key insights into tumor-associated molecular determinants of PCa 
health disparities. 
The molecular content of exosomes represents the molecular profile of the cell 
type that released it (Properzi et al., 2013).  Though a number of studies now describe the 
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association of exosomal markers with several cancer types, only a few exosome based 
diagnostic assays are currently available for clinical use (Properzi et al., 2013).  The 
present study was designed to dissect the PCa exosome from patients of varying 
ethnicities and determine by mass spectrometry if there are ethnic differences in exosome 
protein profiles.  Though we found a large number of novel proteins that appeared to be 
ethnicity-specific, additional studies with larger population cohorts are needed before one 
could unequivocally state that these proteins will help define molecular determinants of 
PCa health disparities.  There may be other factors influencing the shedding of these 
exosomes and their content such as age, diet, and environmental exposures that may 
result from occupation or residence.  The etiology of disease, access to healthcare, or the 
compliance with interventional recommendations may be as important, or more 
important, than the secretome that results from the above etiology.  However, associating 
molecular content with disease content may prove effective in early detection, resulting 
in the saving of thousands of lives. 
In this study, we were able to acquire a random sample of patients from AA, 
Caucasian and Hispanic ethnicities and through molecular and cellular processes extract a 
secretome from the microvesicles called exosomes.  Using mass spectrometry we have 
identified approximately 50 newly identified exosomal proteins that are added to the 
exosome and tumor exosome databases. We are now beginning the arduous process of 
evaluating one, or combinations of these, as putative PCa biomarkers.  The list of 
identified exosomal proteins includes three proteins with previous PCa association: 
Iroquois Homeobox Protein 5 (IRX5), Mitochondrial Tumor Suppressor 1 Isoform 4 
(MTS1), and Trinucleotide repeat containing 6B Isoform 3 (TNR6B) (Table 6). 
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Interestingly, the expression of IRX4 protein, a similar protein to IRX5, has been shown 
in normal prostate tissue and its knockdown is associated with enhanced growth (Nguyen 
et al., 2012).  However, its interaction with vitamin D receptor (VDR) is speculated to be 
necessary for its anticancer function since in the absence of the VDR, PCa susceptibility 
increases (Nguyen et al., 2012).  MTS1, which is also known as a microtubule-associated 
tumor suppressor, inhibits PCa cell proliferation, delays the progression of mitosis by 
prolonging metaphase and reducing tumor growth (Ye et al., 2007).  It too requires a 
number of interacting proteins for its function and is not solely associated with PCa as it 
has also been shown to play a role in breast, brain, ovarian, pancreas, colon, and head & 
neck cancers (Ye et al., 2007).  Of the three putative PCa-associated exosomal proteins, 
TNR6B appears to hold the most promise.  This protein has known interactions with 
novel loci, single nucleotide polymorphisms (SNPs), on TET2 and SYK with interactions 
modifying the risk for PCa (Tao et al., 2012). However, as in the case of MTS1 and 
IRX5, additional studies are needed before these putative biomarkers may be used to 
define risk, presence or even therapeutic response in PCa. 
An important limitation of this study lies in the small number of patients that were 
evaluated from each ethnicity.  In spite of this, we were able to find differences in 
exosomal protein contents between PCa patients and non-Ca controls, and between PCa 
patients from the different ethnic groups.  These results provide initial evidence that 
exosomal profiling may not only yield new PCa biomarkers but also putative molecular 
determinants of PCa health disparities.  Additional studies with larger cohorts of 
ethnically diverse patients and matched controls are guaranteed to identify unequivocally 
exosome derived PCa biomarkers and health disparity determinants. Another limitation 
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was that potentially important proteins were either too small to identify or masked by 
other higher content proteins.  In addition, it may also be problematic that proteins may 
be present in both normal individuals and prostate cancer patients, and it is their 
expression level that defines them as pathologic. This will always be the case with these 
types of proteomic analyses.  Also, patients were selected prior to undergoing any form 
of therapy which would also be informative as the therapeutic stress causes different 
proteins and pathways to be affected, potentially resulting in therapy-associated changes 
in exosomal protein content.  It should be noted, however, that to date, it has not been 
established if treatment causes a radical change in exosome numbers or exosome 
macromolecule content.  Clearly, the clinical relevance of these initial observations 
remain to be established, and it is too early to predict whether the potential exists to adopt 
the three newly identified exosomal proteins in platforms for screening patients for the 
presence of PCa.  Studies with larger cohorts are currently underway in our laboratories 
to evaluate whether these new findings will lead to the identification of molecular 
determinants of PCa health disparities and ultimately to their reduction or elimination. 
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CHAPTER 4 
CONCLUSION 
 
Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer in men 
and the second leading cause of male cancer deaths in the U.S., accounting for 240,890 
new cases and 33,730 deaths in 2011(Brawley, 2012a).  The incidence of the disease has 
an uneven geographic distribution with the highest rates recorded in Australia, North and 
Western Europe and The United States(GLOBOCAN).  The incidence and mortality of 
the disease is almost doubled among blacks compared to other ethnicities in the United 
States(Parkin et al., 2005).  An interesting note is that the disease incidence is lowest 
among African Blacks although some have attributed that to the lack of availability of 
proper statistics from this region of the world(Ferlay et al., 2010). 
A plethora of risk factors for Prostate cancer have been questioned in the 
literature including chronic inflammation of the prostate (infectious and non-infectious), 
hormonal factors (elevated testosterone, leptin etc), smoking, dietary and genetic factors; 
just to name a few.  Smith et al described the link between the susceptibility gene HPC-1 
(Hereditary Prostate Cancer) and an increased risk of developing prostate cancer, 
especially in younger patients(Smith et al., 1996).  Overall, prostate cancer is believed to 
be a disease of multifactorial origin. 
Prostate Specific Antigen (PSA) combined with a digital rectal exam has 
remained the mainstay of screening for prostate cancer for the past two to three decades.  
PSA was first described as a marker for human semen in forensics but it was 
subsequently demonstrated in the serum of men with prostate disease(Stamey et al., 
1987).  The test was however intended for surveillance of diagnosed prostate cancer 
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patients.  There was a sharp rise in newly diagnosed cases in the early 1990’s attributed 
to the introduction of PSA as a screening test for prostate cancer.  Coincident with this 
increase in the number of new cases diagnosed was a pathologic migration toward a more 
favorable (early disease) stage at diagnosis(Derweesh et al., 2004).  Non-palpable 
prostate cancer (and therefore perhaps clinically treatable disease) now accounts for 70-
80% of newly diagnosed cases according to the same authors.  This may at least in part 
explain why the combined 5 and 10 year survival for all stages of prostate cancer is 
currently at 99% and 91% respectively. The true clinical value/advantage of using serum 
PSA as a screening test has been recently called into question.  While the use of this test 
has increased the proportion of patients with lower tumor stage at the time of diagnosis, 
its value is still debated because of its limitations:  1) the cut-off PSA value of 4.0 ng/ml 
fails to detect a significant number of prostate tumors; 2) PSA screening has not been 
demonstrated to improve health outcomes, particularly in older men; 3) PSA is not 
specific for PCa since its levels can be elevated in patients with benign prostatic 
hyperplasia (BPH) and prostatitis, leading to a false-positive finding of up to 60-80% of 
prostate biopsies; and 4) obesity lowers PSA levels(Werny et al., 2007), which in theory 
could lead to delayed detection of PCa and worse clinical outcome.  Moreover, the lack 
of specificity of PSA as a screening tool has also led to too many and sometimes 
unnecessary diagnostic (biopsies) and therapeutic procedures.  The conclusions from the 
European Trial of Prostate-Cancer screening was that 1410 screenings/biopsies had to be 
performed and 48 additional cases treated in order to prevent one death from prostate 
cancer(Schroder et al., 2009).  It is the realization of this need that has led us to devote 
effort to the identification of novel biomarkers that, will enhance early PaCa detection, 
105 
management and therapeutic response.  We recognized that we are not alone in this quest 
but our motivation comes even more so from the fact that efforts in this direction are at 
the best promising but inconclusive. 
The “holy grail” of PCa diagnosis and management is to determine an optimal 
combination of clinical indicators or biomarkers that could detect tumors early with high 
specificity/sensitivity and with limited invasiveness, and that could accurately predict 
which diagnosed men will develop aggressive tumors requiring treatment, and which 
treated men are likely to undergo recurrence and develop advanced, chemoresistant 
disease. In spite of the availability of a plethora of gene products considered as promising 
PCa biomarkers, it is recognized that their combined use with the available clinical 
information is still insufficient for early diagnosis and for guiding individualized 
therapeutic interventions and predicting outcomes.  Their main limitation is that they lack 
specificity and some may require invasive procedures such as biopsies.  However, there 
is growing interest in using proteomics approaches to identify tumor-derived serum 
microvesicles called exosomes and their content, as serological biomarkers. This interest 
stems from the notion that these blood components are considered “sensors” of molecular 
events associated with tumorigenesis. The proteomic and ribonucleic make-up of tumor 
derived exosomes, offers us a snapshot into the ‘internal milieu’ of the tumor 
microenvironment(Yang & Robbins, 2011).  
The very first step toward this journey of novel Biomarker discovery for prostate 
cancer commences with a descriptive analysis of the protein make-up of exosomes 
derived from the sera of patients with prostate cancer.  By comparing this to the 
proteomic profile of exosomes from non-cancer subjects, one hopes to begin to define 
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potential biomarker targets.  Moreover, comparing proteomic profiles across different 
ethnicities may just unmask molecular mechanisms involved in conferring a more 
aggressive disease phenotype among blacks of African descent.  
This quest for a novel biomarker has to begin with a complete and exhaustive 
seroproteomic profiling of the entire proteome of serum derived exosomes of PCa 
patients. A secondary but equally important objective is to identify molecular marker(s) 
that might begin to explain the higher incidence and relatively higher disease severity and 
mortality in the black population.  
The proposed projects associated with this dissertation focused on a critical need 
in the fight against PCa: the identification of novel and promising blood biomarkers that 
could enhance the early detection and management of PCa and the identification of 
molecular markers that may begin to explain the ethnic disparity of the disease. 
Most efforts on the identification of candidate PCa biomarkers, have emphasized 
the analysis of differential gene expression in tumor tissues, methylation patterns, or 
single nucleotide polymorphisms (SNPs) (Saif et al., 2005, Gonda et al., 2011, Gonda & 
Saif, 2011, Smith et al., 2012).  While these efforts are necessary and provide important 
clues for understanding biological mechanisms associated with PCa, it is also imperative 
to develop innovative, non-invasive approaches that analyze indirectly and early in the 
disease process, the molecular profile of prostate tumors.  Recent studies have shown that 
small membrane-bound vesicles called exosomes constitute the latest mode of 
intercellular information transfer or communication (Kharaziha et al., 2012, Vlassov et 
al., 2012).  This exchange of molecular information is facilitated by their unique 
composition, which is enriched with enzymes, structural proteins, adhesion molecules, 
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lipid rafts, microRNAs (miRNAs) and RNAs. An international database (exocarta.org) of 
exosome biomolecules has recorded well over 4,000 proteins and over 2,000 RNA’s. 
Importantly, cancer cells have been shown to secrete more exosomes than do normal 
tissues indicating that exosomes can be used as diagnostic markers and their active 
secretion has functional implications. Not only do cancer cells release more exosomes 
than normal cells but their biomolecular make-up reflects their cell/tissue of origin(Ge et 
al., 2012). 
The studies that have been undertaken in this process have described for the first 
time the entire proteomic make-up of exosomes from PCa patients using exo-profiling 
and seroproteomics approaches, currently considered the most promising strategy for the 
identification of serum biomarkers in human cancers (Tjalsma et al., 2008, Tan et al., 
2009, Kobold, Luetkens, et al., 2010, Kobold, Lutkens, et al., 2010).  We are pleased 
with the works success but in no way believe we have done any more than just begun to 
understand a better method for early detection of cancer in general and prostate cancer in 
specifics. 
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